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A B S T R A C T
Com​pelling ev​i​dence has demon​strated that tu​mor bulk com​prises dis​tinc​tive sub​set of cells gen​er​ally re​!
ferred as can​cer stem cells (CSCs) that has been pro​posed as a strong sus​tainer and pro​moter of tu​mori​ge​n​!
e​sis and ther​a​peu​tic re​sis​tance. These dis​tin​guished prop​er​ties of CSCs have raised in​ter​est in un​der​stand​!
ing the mol​e​c​u​lar mech​a​nisms that gov​ern the main​te​nance of these cells. Nu​mer​ous ex​per​i​men​tal and epi​!
demi​o​log​i​cal stud​ies have demon​strated that ex​po​sure to en​vi​ron​men​tal tox​ins such as the poly​cyclic aro​!
matic hy​dro​car​bons (PAHs) is strongly in​volved in can​cer ini​ti​a​tion and pro​gres​sion. The PAH-in​duced car​!
cino​gen​e​sis is shown to be me​di​ated through the ac​ti​va​tion of a cy​toso​lic re​cep​tor, aryl hy​dro​car​bon re​cep​!
tor (AhR)/​Cy​tochrome P4501A path​way, sug​gest​ing a pos​si​ble di​rect link be​tween AhR and CSCs. Sev​eral
re​cent stud​ies have in​ves​ti​gated the role of AhR in CSCs self-re​newal and main​te​nance, how​ever the mol​e​c​!
u​lar mech​a​nisms and par​tic​u​larly the epi​ge​netic reg​u​la​tions of CSCs by AhR have not been re​viewed be​!
fore. In this re​view, we "rst sum​ma​rize the crosstalk be​tween AhR and can​cer ge​net​ics, with par​tic​u​lar em​!
pha​sis on mech​a​nisms rel​e​vant to CSCs such as Wnt/"-catenin, Notch, NF-#B, and PTEN-PI3K/​Akt sig​nal​ing
path​ways. The sec​ond part of this re​view dis​cusses the re​cent ad​vances and stud​ies high​light​ing the epi​ge​!
netic mech​a​nisms me​di​ated by the AhR path​way that con​trol CSC gene ex​pres​sion, self-re​newal, and
chemore​sis​tance in var​i​ous hu​man can​cers. Fur​ther​more, the re​view also sheds light on the im​por​tance of
tar​get​ing the epi​ge​netic path​ways as a novel ther​a​peu​tic ap​proach against CSCs.
1. Cancer stem cells
Can​cer has be​come the sec​ond lead​ing cause of death world​wide
af​ter car​dio​vas​cu​lar dis​ease. In 2018, around 9.6 mil​lion peo​ple died
of can​cer and this num​ber is ex​pected to in​crease [1]. Can​cer af​fects
peo​ple of dif​fer​ent ages and tar​gets a broad va​ri​ety of or​gans and
cells [1]. De​spite all treat​ment strate​gies, in​clud​ing surgery, ra​di​a​!
tion, and chemother​apy, poor prog​no​sis and high rate of re​cur​rence
is a chal​leng​ing fac​tor of can​cer. A high de​gree of chemore​sis​tance
and re​lapse is ob​served in al​most all types of can​cer which could be
de​"ned by the de​vel​op​ment of a re​gen​er​a​tive sub-pop​u​la​tion of can
cer cells with ac​quired stem​ness prop​er​ties, gen​er​ally known as can​!
cer stem cells (CSCs).
CSCs are a subpop​u​la​tion of can​cer cells with ex​ten​sive abil​ity of
tu​mor ini​ti​a​tion, pro​gres​sion, vas​cu​lar​iza​tion, and metas​ta​sis [2]. It
is pro​posed that CSCs are ei​ther gen​er​ated upon mu​ta​tions in the
nor​mal stem cells of same tis​sue in which tu​mor de​vel​ops, or they
are orig​i​nated at em​bry​onic stages and re​main dor​mant, how​ever,
their mech​a​nism of orig​i​na​tion re​mains un​cer​tain [2–6]. CSCs ac​!
quire the abil​ity to com​pile ge​netic changes over long pe​ri​ods and
es​cape the nor​mal con​trol sys​tem of the body [7]. These cells ex​hibit
spe​ci"c char​ac​ter​is​tics such as in​"​nite pro​lif​er​a​tion po​ten​tials, self-
re​new​ing ca​pac​ity within a tu​mor that can give rise to all other neo
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plas​tic cells found within that tu​mor, en​hanced chemo- and ra​dio-re​!
sis​tance, and high tu​mori​genic​ity with metas​ta​sis and re​lapse prop​!
er​ties [8]. In ad​di​tion, CSCs are char​ac​ter​ized by the abil​ity to form
tu​mor spheres [9,10] and to ex​press high lev​els of ATP-bind​ing cas​!
sette (ABC) drug trans​porters such as ABCG2, that pump nu​mer​ous
en​doge​nous and ex​oge​nous com​pounds out of the cells against the
con​cen​tra​tion gra​di​ent, that leads to a side pop​u​la​tion (SP) which
ap​pears as a dis​tinct dim ‘tail’ in the #ow cy​tom​e​try plot type
[11–13]. More​over, these cells ex​press spe​ci"c cell sur​face mark​ers
that in​clude ep​ithe​lial cell ad​he​sion mol​e​cule (EP​CAM), CD133,
CD44, CD24 [14], alde​hyde de​hy​dro​ge​nase I (ALDH1) [11,12], and
stem​ness genes (Notch1, 2) [9,10]. The iden​ti​"​ca​tion of CSCs was
"rst de​"ned by the com​bined ex​pres​sion of cell sur​face mark​ers,
CD44 /CD24-, in which in​jec​tion of only 200 of these cells was able
to in​duce breast can​cer le​sions in nude mice, whereas 20,000 cells
that did not dis​play this phe​no​type failed to in​duce breast can​cer le​!
sions [15]. In ad​di​tion, ALDH1+ breast CSCs can in​duce tu​mor for​!
ma​tion with as few as 500 cells that are re​sis​tant to con​ven​tional
chemother​apy [16]. More​over, CSCs can also be char​ac​ter​ized based
on some tran​scrip​tion fac​tors such as ctamer bind​ing tran​scrip​tion
fac​tor 4 (OCT4), SRY-box tran​scrip​tion fac​tor 2 (SOX2), Nanog, and
Krüppel-like fac​tor 4 (KLF4) [17].
Nu​mer​ous stud​ies have iden​ti​"ed and char​ac​ter​ized CSCs in
many types of can​cer in​clud​ing leukemia [4,5], breast [15], brain
[18], lung [19,20], and colon [21]. The CSCs have been shown to
be po​ten​tially re​spon​si​ble for tu​mor ma​lig​nancy, chemore​sis​tance,
and tu​mor re​cur​rence [8,22]. Ac​cu​mu​lat​ing re​ports in​di​cate that
highly re​frac​tory and ag​gres​sive tu​mors con​tain in​creased num​ber of
CSCs [19,20]. Ev​i​dence pro​pose that can​cer in​va​sion and metas​ta​sis,
which even​tu​ally lead to the pa​tient’s death is in​ter​vened by
chemore​sis​tant CSCs [9]. Thus, it is cur​rently ac​cepted that fail​ure to
erad​i​cate CSC pop​u​la​tions se​verely lim​its the ul​ti​mate ef​fec​tive​ness
of many cur​rent can​cer ther​a​pies, and hence elim​i​na​tion of CSCs is
crit​i​cal to im​prove treat​ment out​comes and to re​duce re​cur​rence and
re​lapse. There​fore, in or​der to im​ple​ment new treat​ment reg​i​men,
com​pre​hen​sive un​der​stand​ing of CSC ini​ti​a​tion, sur​vival, and the
meta​bolic as well as sig​nal​ing path​ways in​volved war​rant fur​ther in​!
ves​ti​ga​tion.
In nor​mal con​di​tions, sig​nal​ing path​ways that reg​u​late nor​mal
stem cells equi​lib​rium are highly co​or​di​nated and con​trolled [10].
No​tably in can​cer, these path​ways are ei​ther re​pressed or ab​nor​!
mally struc​tured where these dis​tinct ab​nor​mal​i​ties and vari​a​tions
con​trol the self-re​newal, pro​lif​er​a​tion, sur​vival, and dif​fer​en​ti​a​tion
prop​er​ties of CSCs. Re​search has proven that these path​ways are not
lin​ear, but rather in​ter​wind to​gether lead​ing to an in​ter-path​way
crosstalk. Ex​am​ples of the most stud​ied path​ways that con​trol CSCs
pro​gres​sion, self-re​newal, and chemore​sis​tance in​clude Wnt/"-
catenin, Notch, Janus ki​nase (JAK)/​sig​nal trans​ducer and ac​ti​va​tor
of tran​scrip​tion (STAT) [10], Hedge​hog [23], phos​pho​inosi​tide 3-ki​!
nase (PI3K)/ Phos​phatase and tensin ho​molog (PTEN), and nu​clear
fac​tor #-B (NF-#B) [24]. How​ever, the de​vel​op​ment and pro​gres​sion
of CSCs can​not be only at​trib​uted to ge​netic reg​u​la​tions, in fact,
changes in CSCs in​clud​ing DNA methy​la​tion, chro​matin re​mod​el​ing,
and non-cod​ing RNA, which are known as epi​ge​netic mod​i​"​ca​tions,
have been re​cently shown to reg​u​late can​cer gene ex​pres​sion and
im​pact CSCs for​ma​tion and main​te​nance [25,26]. Epi​ge​netic mod​i​"​!
ca​tions of the genome are sim​ply de​"ned as an al​ter​ation of the ge​!
netic code, with​out changes on the DNA se​quences, to con​trol cel​lu​!
lar de​vel​op​men​tal hi​er​ar​chies. These epi​ge​netic mod​i​"​ca​tions
crosstalk with ge​netic and post-trans​la​tional mech​a​nisms in CSCs of
dif​fer​ent types of can​cer to con​trol their pro​lif​er​a​tion, self-re​newal,
and chemore​sis​tance. In​ter​est​ingly, it has been re​ported that early-
life ex​po​sure to en​vi​ron​men​tal pol​lu​tants and car​cino​gens such as
poly​cyclic aro​matic hy​dro​car​bons (PAHs) is ac​com​pa​nied by epi​ge
netic mod​i​"​ca​tions, sug​gest​ing in​ter​ac​tions be​tween ge​netic, epi​ge​!
netic, and en​vi​ron​men​tal fac​tors. Know​ing that PAHs me​di​ate car​!
cino​genic​ity and tu​mor​genic​ity through ac​ti​va​tion of a cy​toso​lic re​!
cep​tor, the aryl hy​dro​car​bon re​cep​tor (AhR) [25,26], the crosstalk
be​tween CSCs-reg​u​lat​ing genes and AhR path​way through epi​ge​netic
mech​a​nisms has not been re​viewed be​fore.
2. The Aryl hydrocarbon receptor
AhR is a cy​toso​lic DNA bind​ing lig​and ac​ti​vated tran​scrip​tional
fac​tor, reg​u​lat​ing the ex​pres​sion of cer​tain genes in​volved in xeno​bi​!
otic me​tab​o​lism [27–29]. AhR was pri​mar​ily iden​ti​"ed as a reg​u​la​!
tor of bi​o​log​i​cal and tox​i​co​log​i​cal re​sponses to en​vi​ron​men​tal toxic
pla​nar aro​matic hy​dro​car​bons such as PAHs and syn​thetic halo​!
genated aro​matic hy​dro​car​bons (HAHs) which have high a%n​ity to​!
wards AhR [30–32]. As of its role in xeno​bi​otic me​tab​o​lism, AhR
has been stud​ied ex​ten​sively for many years in tox​i​col​ogy, phar​ma​!
col​ogy, and in the "eld of med​i​cine such as, neu​ro​log​i​cal dis​eases
[33], car​dio​vas​cu​lar dis​eases [34], and can​cer [35].
2.1. Molecular regulation of AhR and target genes
AhR ex​ists in the cy​to​plasm as a het​eromeric core com​plex bound
with dis​tinct chap​er​one pro​teins such as heat shock pro​teins 90
(HSP90) and im​munophilin-like pro​tein XAP2. AhR is ac​ti​vated and
in​duced by a group of en​vi​ron​men​tal pol​lu​tants such as 2,3,7,8-
tetra​chlorodibenzo-p-dioxin (TCDD), 7,12-di​methyl​benz[a]an​!
thracene (DMBA), benzo[a]pyrene (BaP), 3-methyl​cholan​threne (3-
MC), and "-naph​tho#avone ("-NF) [30–32]. Im​me​di​ately af​ter lig​!
and bind​ing, AhR un​der​goes cer​tain con​for​ma​tional changes and
then translo​cates to the nu​cleus where it het​erodimer​izes with a nu​!
clear translo​ca​tor, aryl hy​dro​car​bon nu​clear translo​ca​tor (ARNT).
The AhR-ARNT com​plex then binds with spe​ci"c DNA se​quences,
Xeno​bi​otic Re​sponse El​e​ment (XRE), lo​cated in the en​hancer re​gion
of cer​tain genes, re​sult​ing in the tran​scrip​tional ac​ti​va​tion of en​!
zymes in​volved in xeno​bi​otic me​tab​o​lism, such as the cy​tochrome
P450 (CYP) en​zymes 1A1 (CYP1A1), CYP1B1, CYP1A2, AhR re​pres​!
sor (AhRR), and the anti-ox​i​dant genes, such as NAD(P)Quinone ox​i​!
dore​duc​tase 1 (NQO1) and glu​tathione s-trans​ferase (GSTA1)
[36,37]. In​duc​tion of CYP1A1 and CYP1B1 me​di​ates the bio​trans​for​!
ma​tion of the en​vi​ron​men​tal pol​lu​tants and pro-car​cino​genic chem​i​!
cals into highly car​cino​genic and re​ac​tive diol-epox​ide (DE) in​ter​me​!
di​ates [36,37]. The re​sul​tant in​ter​me​di​ates in​ter​ca​late with DNA,
form​ing adducts and ac​ti​vate cy​to​toxic genes which me​di​ate cell mu​!
ta​tion and tu​mor ini​ti​a​tion (Fig. 1) [29].
CYP1A1, among other CYPs, is highly ca​pa​ble of bioac​ti​vat​ing
toxic and en​vi​ron​men​tal con​t​a​m​i​nants, PAHs and HAHs, to car​cino​!
genic metabo​lites and thus is con​sid​ered a use​ful bio​marker of ex​po​!
sure to en​vi​ron​men​tal car​cino​gens [38]. The car​cino​genic role of
CYP1A fam​ily is sup​ported by the fact that DMBA, a well-known
AhR lig​and, in​duces can​cer in wild type, but not cyp1a1 knock​out
mice [39]. Al​though CYP1A1 is ex​pressed at low lev​els in the lung
and pla​centa [40,41], it is highly in​ducible in al​most all tis​sues of
most mam​malian species in​clud​ing hu​man, rat, mouse, and rab​bit
[42]. CYP1B1, on the other hand, is a tu​mor-re​lated form of CYPs
which is con​sti​tu​tively ex​pressed in ex​tra​hep​atic tis​sues and is
markedly over​ex​pressed in a wide va​ri​ety of pri​mary tu​mors [43]. In
this re​gard, the high ex​pres​sion lev​els of CYP1B1 in tu​mor tis​sues,
with lack of ex​pres​sion in nor​mal tis​sues, was found to be par​tially
reg​u​lated through pro​tea​so​mal degra​da​tion of the en​zyme [44] and
by both tran​scrip​tional and post-trans​la​tional mech​a​nisms [45]. On
the other hand, two AhR-reg​u​lated genes, AhRR and NQO1, have
been shown to pro​tect against the car​cino​genic role of AhR. AhRR is
a spe​ci"c com​pet​i​tive re​pres​sor of AhR that com​petes with ARNT to
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Fig. 1. Mol​e​c​u​lar path​way of AhR ac​ti​va​tion and tu​mor ini​ti​a​tion.
ac​ti​va​tion of AhR and sup​pres​sion of the tran​scrip​tional in​duc​tion of
CYP1 genes, and thus AhRR serves as a tu​mor sup​pres​sor gene in
sev​eral types of can​cer cells [46]. NQO1, on the other hand, is an
anti-ox​i​dant and detox​i​fy​ing gene that pro​tects cells against var​i​ous
chem​i​cal stresses and car​cino​gen​e​sis through cat​alyz​ing the two-
elec​tron re​duc​tion which leads to re​mov​ing the diol-epox​ide group
(Fig. 1) [47]. The pro​tec​tive ef​fect of NQO1 is sup​ported by the
"nd​ing that NQO1 knock​out mice are more sus​cep​ti​ble to DMBA-in​!
duced can​cer than their wild-type lit​ter​mates [48].
The pre​sent re​view fo​cuses on ex​plor​ing the im​pact of epi​ge​netic
reg​u​la​tion of AhR path​ways par​tic​u​larly CYP-reg​u​lated genes
(CYP1A1 and CYP1B1), on CSCs de​vel​op​ment, self-re​newal, and
chemore​sis​tance.
2.2. The regulatory e!ects of AhR/​CYP1 pathway on CSCs’
Development, Self-​renewal, and Chemoresistance
The AhR/​CYP1 path​way is known to have tu​mor ac​ti​va​tor or
sup​pres​sor ac​tiv​i​ties de​pend​ing on the phe​no​type of the tar​get can​!
cer cells. The role of AhR/​CYP1 path​way in car​cino​gen​e​sis and can​!
cer ini​ti​a​tion as well as its po​ten​tial use as a ther​a​peu​tic tar​get has
been stud​ied in breast can​cer [49] glioblas​toma [50], gas​tric can​cer
[50], lym​phoma [51], colon can​cer [52], ovar​ian and chori​o​car​ci​!
noma [9], melanoma [53], leukemia [54], mul​ti​ple myeloma [55],
lung can​cer [56], liver can​cer [57], and prostate can​cers [58]. Since
CSCs are known to be tu​mor-ini​ti​at​ing cells and are ma​jor tar​gets for
chem​i​cal car​cino​gens, it is highly hy​poth​e​sized that AhR plays a role
in con​trol​ling CSCs. The hy​poth​e​sis that AhR ac​ti​va​tion en​hances
CSCs self-re​newal and pro​gres​sion is sup​ported by sev​eral re​ports
which showed that CSCs of dif​fer​ent can​cer types ex​hibit a higher
ex​pres​sion and func​tional lev​els of AhR than cor​re​spond​ing dif​fer​en​!
ti​ated non-CSCs. The ac​ti​va​tion of AhR in dif​fer​ent hu​man can​cer
cells is as​so​ci​ated with in​creased CSC char​ac​ter​is​tics such as tu​mori​!
genic po​ten​tial, cell pro​lif​er​a​tion, chemore​sis​tance, ALDH  cells,
and the num​ber and size of spheres for​ma​tion [59–62]. In in-vivo
can​cer tis​sues, AhR has been found to be con​sti​tu​tively ac​tive as
com​pared to nor​mal tis​sues, in which low AhR ex​pres​sion lev​els are
as​so​ci​ated with re​duced tu​mor size and a bet​ter over​all pa​tient sur​!
vival rate [63].
AhR reg​u​lates tu​mori​ge​n​e​sis through the main​te​nance of CSC
char​ac​ter​is​tics [59]. It me​di​ates these char​ac​ter​is​tics through con​!
trol​ling drug re​sis​tance and cell pro​lif​er​a​tion [59,64]. Mul​ti​ple stud​!
ies have shown that the knock​down of AhR in breast CSCs and sub​!
se​quent treat​ment with chemother​a​peu​tic agents de​creased the cell
vi​a​bil​ity and in​creased the chemosen​si​tiv​ity as ev​i​denced by in​duced
apop​to​sis lev​els [49], whereas in​duc​tion of AhR us​ing 3-MC was as​!
so​ci​ated with in​creased ALDH  cell pop​u​la​tion in chemore​sis​tant,
but not in chemosen​si​tive, hu​man breast can​cer MCF7 cells [65].
This was fur​ther sup​ported by sev​eral "nd​ings where, the in​jec​tion
of nude mice with breast can​cer cells ex​press​ing low AhR level and
re​sis​tance to ta​mox​ifen, de​layed tu​mor for​ma​tion [65]. This in​di​!
cates that AhR ac​ti​va​tion is as​so​ci​ated with drug re​sis​tance and its
re​duced ex​pres​sion in​creases chemosen​si​tiv​ity in can​cer cells.
On the con​trary to the promi​nent "nd​ings, sev​eral stud​ies have
re​ported in​verse ef​fect of AhR ac​ti​va​tion on CSC de​vel​op​ment and
self-re​newal. This hy​poth​e​sis is also sup​ported by sev​eral stud​ies, for
in​stance, Zhao et al., have re​ported that ac​ti​vat​ing AhR and in​duc​!
tion of CYP1A1 ex​pres​sion in MCF-7 cell lines, by "-NF, re​presses the
mam​mos​phere for​ma​tion and the size and rate of sec​ondary sphere
for​ma​tion [66]. These ef​fects of AhR ac​ti​va​tion on CSCs were as​so​ci​!
ated with a de​crease in CSC mark​ers such as ex​pres​sion of Notch,
Bim1, "-catenin, Nanog, and ALDH  cells [66]. This re​versed cor​re​!
la​tion be​tween ALDH and AhR was re​ported in both hu​man (A375
and C8161) and murine (B16-F10) melanoma cell lines, in which se​!
quence analy​sis of the ALD​H1A1 gene in murine melanoma cells
demon​strated the pres​ence of four XRE bind​ing sites, sug​gest​ing a
tran​scrip​tional ef​fect [67]. In ad​di​tion, it was re​ported that ac​ti​va​!
tion of AhR/​CYP1B1 in hu​man acute myeloid leukemia (AML) cell
lines (MOLM-14 and MV4-11) by 6-formylin​dolo[3,2-b]car​bazole
(FICZ) de​creases CSCs pop​u​la​tion and in​va​sion while in​creases the
apop​to​sis level, whereas chem​i​cal or ge​netic in​hi​bi​tion of AhR/​
CYP1A1 in​creases the CSC pop​u​la​tions, char​ac​ter​is​tics, and tu​mori​!
genic​ity [68]. Sim​i​lar ef​fects were also re​ported in prostate can​cer
[69], colon [70], and liver [71]. These stud​ies sup​port an​ti​tu​mori​!
genic ac​tiv​ity of AhR and shed the light on the po​ten​tial of AhR ag​o​!
nists in the treat​ment of can​cer. The tis​sue-spe​ci"c vari​a​tions in re​!
sponse to AhR ag​o​nist or an​tag​o​nist could be at​trib​uted to sev​eral
fac​tors such as lig​and-in​duced con​for​ma​tional changes in the re​cep​!
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clear co​fac​tors that ex​hibit tis​sue-spe​ci"c ex​pres​sion [72]. These dis​!
crep​an​cies war​rant fur​ther in​ves​ti​ga​tions to ex​plore the mol​e​c​u​lar
mech​a​nisms me​di​at​ing the ef​fects of AhR/​CYP1 in the de​vel​op​ment,
main​te​nance, and chemore​sis​tance of CSCs.
2.3. Molecular pathways mediating the e!ect of AhR/​CYP1A1 on CSCs
How does the AhR mod​u​late CSCs? What are the mol​e​c​u​lar
mech​a​nisms and path​ways in​volved? Un​for​tu​nately, these ques​tions
have not been an​swered de​"n​i​tively. Al​though the ef​fects of AhR/​
CYP1 ac​ti​va​tors, par​tic​u​larly TCDD, DMBA, 3-MC, and BaP, on the
CSCs of dif​fer​ent can​cer types have been ex​am​ined in sev​eral
species, lit​tle is known about the mol​e​c​u​lar path​ways in​volved. This
sec​tion pre​sents a de​scrip​tion of the most stud​ied mol​e​c​u​lar path​!
ways that me​di​ate the reg​u​la​tion of CSCs by AhR/​CYP1A1 ac​ti​va​tors
or in​hibitors in sev​eral can​cer types of dif​fer​ent species. In gen​eral,
"ve main mech​a​nisms are pro​posed: 1) Wnt/"-catenin path​way, 2)
Notch path​way, 3) NF-#B path​way, 4) PTEN-PI3K/​Akt path​way, and
5) re​sis​tance-me​di​at​ing path​ways. Table 1 sum​ma​rizes these mech​a​!
nisms in dif​fer​ent can​cer types.
2.3.1. Wnt/​!-​catenin pathway
Wnt fam​ily of se​creted gly​col​ipopro​teins plays ma​jor roles in cell
pro​lif​er​a​tion, cell po​lar​ity, and cell fate de​ter​mi​na​tion dur​ing em​bry​!
onic de​vel​op​ment and tis​sue home​osta​sis [73]. The Wnt sig​nal​ing
path​way is a sig​nal trans​duc​tion path​way that op​er​ates via pass​ing
sig​nal from out​side to the in​side of the cell through cell sur​face re​!
cep​tors [74]. Ac​ti​va​tion of Wnt re​cep​tors blocks the GSK3" ac​tiv​ity
and the degra​da​tion of "-catenin, which is translo​cated to the nu​!
cleus where it in​ter​acts with mem​bers of the T cell fac​tor (TCF)/​lym​!
phoid en​hancer-bind​ing fac​tor (LEF) fam​ily of tran​scrip​tion fac​tors
to ac​ti​vate Wnt tar​get gene tran​scrip​tion [75]. Wnt sig​nal​ing path​!
way plays an im​por​tant role in CSC me​di​ated metas​ta​sis and stem​!
ness [10]. CSCs ex​press el​e​vated level of Wnt sig​nal​ing pro​teins,
such as LEF1, cy​clin D1, "-catenin, and TCF-4 [10]. The knock​down
of the Wnt pro​teins has been shown to de​crease the ex​pres​sion of
stem​ness genes (CD44, ALDH1, and Sca-1), re​duce mam​mos​phere
for​ma​tion, and di​min​ish CSC pop​u​la​tion in can​cer cells [10]. Wnt
sig​nal​ing path​way is also in​volved in reg​u​la​tion of self-re​newal of
the CSCs through "-Catenin/​TCF tran​scrip​tion fac​tor [76]. The as​so​!
ci​a​tion be​tween Wnt sig​nal​ing and AhR in dis​ease de​vel​op​ment has
been proven by Schnei​der and his team [77]. The crosstalk be​tween
AhR and Wnt/"-catenin for the reg​u​la​tion of CSCs has been sup​!
ported by sev​eral pieces of ev​i​dence. First, ac​ti​va​tion of "-catenin en​!
hances the AhR trans​ac​ti​va​tion and ac​tiv​ity via phys​i​cal in​ter​ac​tion
with its DNA re​spon​sive el​e​ments [78]. The ac​ti​va​tion of AhR
through "-catenin sup​ports the fact that "-catenin in​ter​acts with cer​!
tain tran​scrip​tion fac​tors and in​creases their tran​scrip​tional ac​tiv​ity
[79,80]. Sec​ond, in​duc​tion of AhR/​CYP1 causes ac​ti​va​tion and nu​!
clear translo​ca​tion of "-catenin in breast CSCs and en​hances ex​pres​!
sion of its down​stream tar​get Cy​clin D1 [49]. This is sup​ported by
the ob​ser​va​tions that CYP1B1 fos​ters can​cer cell pro​lif​er​a​tion as well
as metas​ta​sis via ep​ithe​lial-mes​enchy​mal tran​si​tion (EMT) and Wnt
path​ways [81]. In in​#am​ma​tory breast can​cer SUM149 cells, it has
been re​ported that dele​tion of AhR with CRISPR-Cas9 gene edit​ing
or CYP1B1 knock​down re​duces the mRNA ex​pres​sion of Wn​t5a/​b
and "-catenin, which are cor​re​lated with in​creased lymph node
metas​ta​sis and CD44 /CD24- cells [82]. Al-Dhfyan et al., and oth​ers
have also re​ported a crosstalk be​tween AhR and Wnt/"-catenin in
CSCs of breast can​cer MCF-7, Hs578 T, and SUM149 cells, in that ac​!
ti​va​tion of AhR/​CYP1A1 by DMBA or TCDD sig​nif​i​cantly in​creased
breast CSCs prop​er​ties such as "-catenin ex​pres​sion, ALDH  cells, SP
cells, and mam​mos​phere for​ma​tion, whereas, ge​netic and chem​i​cal
In ad​di​tion, in​hi​bi​tion of Wnt/"-catenin by XAV-939, blocks CSCs in​!
duc​tion by the AhR ac​ti​va​tor, sug​gest​ing that AhR in​creases CSCs
pop​u​la​tion through Wnt/"-catenin path​way [49].
2.3.2. Notch pathway
The Notch sig​nal​ing is a trans​duc​tion path​way that is es​sen​tial
for the reg​u​la​tion of em​bry​onic de​vel​op​ment in nu​mer​ous meta​zoan
or​gan​isms [83]. In adult tis​sue, ac​ti​va​tion of the Notch1 path​way
me​di​ates con​text-spe​ci"c func​tions, such as self-re​newal and T-cell
dif​fer​en​ti​a​tion. Notch sig​nal​ing is es​sen​tial for stem and prog​en​i​tor
cell func​tions in sev​eral tis​sues [10]. The cells that ex​hibit higher
Notch ac​tiv​ity have in​creased CSC char​ac​ter​is​tics and tu​mor ini​ti​at​!
ing prop​er​ties [84]. In ad​di​tion, Notch sig​nal​ing path​way is as​so​ci​!
ated with pro-sur​vival genes which reg​u​late self-re​newal and pro​lif​!
er​a​tion of the can​cer cells [84–87]. Dys​reg​u​la​tion of Notch sig​nal​ing
has been ob​served in var​i​ous can​cers [88]. CSCs de​rived from pan​!
cre​atic can​cer ex​pressed el​e​vated lev​els of the Notch sig​nal​ing genes,
Notch1 and Notch3 and its tar​get gene Hairy and En​hancer of Split
ho​molog 1 (Hes1) [10]. Upon knock​down of the Hes1 gene in pan​!
cre​atic can​cer pri​mary xenografts, the CSC mam​mos​phere for​ma​tion
de​creased, whereas treat​ing the CSCs with Notch ag​o​nists showed an
in​crease in mam​mos​phere for​ma​tion [10]. Ac​cu​mu​lat​ing ev​i​dence
in​di​cates that Notch re​duces the ex​pres​sion of PTEN, a tu​mor sup​!
pres​sor gene, and en​hances the ex​pres​sion of c-Myc onco​gene [89].
Ev​i​dence sup​port​ing the crosstalk be​tween AhR and Notch was re​!
ported by Alam et. al., who demon​strated that ac​ti​va​tion of Notch
sig​nal​ing path​way in lung can​cer cells in​duces AhR by en​hanc​ing the
se​cre​tion of en​doge​nous lig​ands which sub​se​quently stim​u​lates in​ter​!
leukin-22 (IL-22) se​cre​tion from CD4  T cells [90]. IL-22 is specif​i​!
cally over​ex​pressed in serum and tis​sue of re​cur​rent non-small cell
lung can​cer (NSCLC) and pro​motes can​cer cell pro​lif​er​a​tion and mi​!
gra​tion which are char​ac​ter​is​tics of CSCs [91]. More​over, IL-22 also
in​duces cell in​va​sion in lung ade​no​car​ci​noma cell line A549 which is
a fun​da​men​tal fea​ture of CSCs [91]. On the other hand, Al-Dhfyan et
al., have shown that ac​ti​va​tion of the AhR/​CYP1A1 path​way in hu​!
man breast can​cer MCF-7 cells by TCDD did not sig​nif​i​cantly al​ter
the basal ex​pres​sion and translo​ca​tion of ICN-1, a Notch tran​scrip​!
tion fac​tor, and the chem​i​cal in​hi​bi​tion of the Notch path​way by FLi-
06 did not re​verse the ef​fect of AhR ac​ti​va​tor DMBA on the in​duc​!
tion of CSCs mark​ers [49]. In liver can​cer, it has been re​ported that
hu​man pri​mary he​pa​to​cel​lu​lar car​ci​noma tis​sues and cell lines ex​!
press high lev​els of Notch1 which is as​so​ci​ated with over​ex​pres​sion
of AhR com​pared to nor​mal he​patic cells [92]. Fur​ther​more, ac​ti​va​!
tion of AhR in rat he​patic stem cells with TCDD in​creased cell pro​lif​!
er​a​tion and for​ma​tion of stem cell colonies [93]. Taken to​gether,
these re​sults clearly sug​gest that AhR dif​fer​en​tially reg​u​lates the
func​tion and ac​tiv​ity of Notch path​way in CSCs.
2.3.3. NF-​"B pathway
NF-#B sig​nal​ing path​way reg​u​lates ra​diore​sis​tance and can​cer
pro​gres​sion through I#B ki​nase $ (IKK$). It causes ex​pan​sion and
self-re​newal of tu​mor-ini​ti​at​ing cells and metas​ta​sis in prostate and
breast can​cer [94,95]. More​over, IKK$ reg​u​lates the ex​pres​sion of
stem​ness-re​lated genes and en​hances CSCs de​vel​op​ment and
chemore​sis​tance through AhR-de​pen​dent mech​a​nism [28]. In CSCs,
it has been shown that IKK$ co-lo​cal​izes with AhR in the nu​cleus
and in​ter​acts with the pro​moter of stem​ness-re​lated genes. Ad​di​tion​!
ally, this en​rich​ment of IKK$ at the pro​mot​ers of stem​ness-re​lated
genes is de​pen​dent on AhR ac​ti​va​tion as the de​ple​tion of AhR re​!
duces the con​cen​tra​tion of IKK$ at their pro​mot​ers. This in​di​cates
that AhR to​gether with IKK$ pro​mote CSC char​ac​ter​is​tics through
colo​cal​iza​tion in nu​cleus [28]. In ad​di​tion to IKK$, the NF-#B sub​!
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Table 1
Mech​a​nisms in​volved in the mod​u​la​tion of CSCs by AhR/​CYP1 path​ways.
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been shown that ac​ti​va​tion of AhR through TCDD in hu​man breast
can​cer cells, MCF-7 and MDA-MB-436, in​duced IL-8 ex​pres​sion and
RelB re​sult​ing in de​creased cell apop​to​sis and in​creased cell pro​lif​er​!
a​tion. This ef​fect was fur​ther sup​ported by ac​ti​va​tion of apop​to​sis in
ER$-neg​a​tive cell lines by knock​down of AhR or RelB [96]. In hu​!
man os​teosar​coma MG-63 cell line, the ac​ti​va​tion of AhR through
TCDD was as​so​ci​ated with in​creased pro​tein and mRNA lev​els of re​!
cep​tor ac​ti​va​tor of NF-#B lig​and (RANKL) [97]. The RANK/​RANKL
per​mits de​vel​op​ment of can​cer cells and plays a role in the for​ma​!
tion of pri​mary and sec​ondary tu​mors in leukemia, breast can​cer,
bone can​cer, and prostate can​cer [98]. Whereas, the in​hi​bi​tion of
RANKL in mouse mod​els re​sulted in re​duced mam​mary tu​mori​ge​n​e​!
sis and pul​monary metas​ta​sis [99]. This sug​gests that AhR par​tic​i​!
pates in the de​vel​op​ment of can​cer through the ac​ti​va​tion of RANKL
which plays a role in CSC in​va​sion and metas​ta​sis.
2.3.4. PTEN-​PI3K/​Akt pathway
The PTEN-PI3K/​AKT is an in​tra​cel​lu​lar sig​nal​ing path​way that
plays an im​por​tant role in reg​u​lat​ing the cell cy​cle and thus it is di​!
rectly re​lated to cel​lu​lar qui​es​cence, pro​lif​er​a​tion, can​cer, and cel​lu​!
lar longevity. PI3K ac​ti​va​tion phos​pho​ry​lates and ac​ti​vates Akt,
char​ac​ter​is​tics, whereas, ac​ti​va​tion in​creases the EMT, a fea​ture of
CSCs, in hu​man breast can​cer MCF-7 and MDA-MB-231 cells through
in​duc​tion of miR-21 [104]. The in​volve​ment of the AhR/​CYP1 path​!
way in reg​u​lat​ing PI3K/​Akt in CSCs has been demon​strated in sev​!
eral types of can​cer. In breast can​cer cells, it has been re​ported that
ac​ti​va​tion of AhR/​CYP1A1 re​sult in in​creased ex​pres​sion of Akt
which in​duces CSC fea​tures such as ALDH  cells, SP cells, and mam​!
mos​phere for​ma​tion [49,105]. In ad​di​tion, in​hi​bi​tion of PI3K/​Akt
path​way in breast can​cer MCF-7 cells by LY294002 blocked the AhR-
in​duced CSCs pop​u​la​tion [49]. Fur​ther​more, ac​ti​va​tion of AhR in
breast CSCs re​duced the ex​pres​sion of PTEN, a tu​mor sup​pres​sor
gene and a neg​a​tive reg​u​la​tor of PI3K/​Akt, which per​mits CSCs self-
re​newal, pro​lif​er​a​tion, and un​dif​fer​en​ti​a​tion through reg​u​la​tion of c-
Myc [49,106]. In lung can​cer, ac​ti​va​tion of AhR in NSCLC H1975
cells in​creases Akt phos​pho​ry​la​tion which is as​so​ci​ated with in​!
creased chemore​sis​tance to ty​ro​sine ki​nase in​hibitor, Afa​tinib,
through ac​ti​va​tion of Src and MEK/​ERK sig​nal​ing path​way, whereas
the knock​down of AhR in​hibits cell pro​lif​er​a​tion and en​hances the
chemosen​si​tiv​ity [107]. Sim​i​lar ob​ser​va​tions were re​ported in
H1975 AhR shRNA xenograft tu​mors char​ac​ter​ized by com​plete re​!




























which in turn reg​u​lates the ex​pres​sion of car​cino​gen​e​sis-re​lated
genes such as "-catenin, p21, p27, Mdm2, and Fork​head tran​scrip​!
tion fac​tors [100,101]. PI3K/​Akt path​way is as​so​ci​ated with con​fer​!
ring chemore​sis​tance, cell pro​lif​er​a​tion, and sur​vival [89,102,103].
In​ac​ti​va​tion of PI3K/​Akt path​way is as​so​ci​ated with de​creased CSCs​
he​patoma He​pa1c1c7 lack​ing AhR (LA1) ex​hibits lower level of
PI3K/​Akt ac​tiv​ity than wild-type He​pa​p1c1c7 cells, which leads to
in​creased sus​cep​ti​bil​ity to apop​to​sis [108]. On the con​trary, Zhao et
al., and col​leagues have re​ported that ac​ti​va​tion of the AhR by 2-(1'
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an AhR ag​o​nist, in glioblas​toma U87 cell lines leads to im​paired Akt
ac​tiv​ity, in​creased apop​to​sis func​tion, and de​creased the CSC
marker, OCT4 ex​pres​sion, in U87 spher​oids [66]. Sim​i​lar ob​ser​va​!
tions were also re​ported in nude mice trans​planted with liver can​cer
HC​CLM3 cells [66]. These "nd​ings in​di​cate a cor​re​la​tion be​tween
AhR and PTEN-PI3K/​Akt path​way for main​te​nance of CSCs.
2.3.5. Drug Resistance-​mediating pathways
Dur​ing tu​mor pro​gres​sion, chemore​sis​tance is the lead​ing cause
of treat​ment fail​ure and dis​ease re​lapse in can​cer pa​tients [109]. It
is well-re​ported that most of the chemore​sis​tant cells ex​press high
CSC char​ac​ter​is​tics and fea​tures, such as self-re​newal and tu​mor​!
genic​ity [109]. AhR has been shown to me​di​ate chemore​sis​tance in
CSCs by reg​u​lat​ing the ex​pres​sion of sev​eral genes, such as ABCG2.
ABCG2 is a mem​ber of the ABC fam​ily G, known also as breast can​!
cer re​sis​tant pro​tein (BCRP), that pro​tects cells and tis​sues against
xeno​bi​otics. Over​ex​pres​sion of ABCG2 con​tributes to mul​tidrug re​sis​!
tance in can​cer and CSCs by its ca​pac​ity to ef​#ux many chemother​a​!
peu​tic agents [59,65]. The link be​tween ABCG2 and chemore​sis​!
tance in CSCs has been demon​strated by Dubrovska et al., who
showed that drug re​sis​tant MCF-7 breast can​cer cells, which ex​press
higher lev​els of ABCG2, ex​hibit in​creased CSC mark​ers such as SP
cells and ALDH en​zy​matic ac​tiv​ity [65]. The AhR crosstalk with
ABCG2 has been es​tab​lished in the stem cells of sev​eral can​cer types.
ABCG2 has been re​ported to be tran​scrip​tion​ally ac​ti​vated by the
AhR/​CYP1 path​ways through bind​ing of AhR to the XRE se​quence
on ABCG2 pro​moter re​gion [59,110–112]. In​ter​est​ingly, the in​hi​bi​!
tion of AhR in ra​dio-re​sis​tant lung ade​no​car​ci​noma A549 cell line,
re​duced ex​pres​sion of ABCG2 which is as​so​ci​ated with re​duc​tion of
many stem​ness marker genes such as ALD​H1A1, KLF4, chemokine
re​cep​tor type 4 (CX​CR4), c-Myc, and Lgr6 which in​di​cates the as​so​!
ci​a​tion of AhR with a num​ber of tu​mor in​duc​ing genes [28]. Fur​!
ther​more, over​ex​pres​sion of ABCG2 in ta​mox​ifen re​sis​tant MCF-7
xenograft tu​mors which was as​so​ci​ated with in​creased CSCs mark​ers,
SP cells, and ALDH ac​tiv​ity, was blocked by in​hi​bi​tion of CX​CR4
[65], a chemokine re​cep​tor that is known to be in​duced by AhR ac​ti​!
va​tion by TCDD [97]. In ad​di​tion, chori​o​car​ci​noma spher​oid cells
(JEG-3 and BeWo) with CSC prop​er​ties ex​hib​ited el​e​vated ex​pres​sion
of AhR, ABCG2, and stem​ness mark​ers Sox2, Oct4, Nanog, and
CD44/​CD133 [59]. There​fore, these "nd​ings re​veal that ac​ti​va​tion
of AhR/​CYP1A1 path​way in​creases ABCG2-me​di​ated chemore​sis​!
tance.
An​other gene that is known to me​di​ate AhR-in​duced CSCs pop​u​!
la​tion is SOX2. SOX2 is a tran​scrip​tion fac​tor that plays a role in
main​tain​ing stem​ness of em​bry​onic stem cells and hence its dys​reg​u​!
la​tion has im​pact on can​cer cell pro​lif​er​a​tion, in​va​sion, self-re​newal,
and chemore​sis​tance [113]. Stan​ford et al., have demon​strated that
AhR ac​ti​va​tion in hu​man TNBC Hs578 T and in​#am​ma​tory breast
can​cer SUM149 cells in​creases SOX2 ex​pres​sion and nu​clear translo​!
ca​tion through di​rect AhR-SOX2 bind​ing, lead​ing to in​creased
ALDH  cells and chemore​sis​tance [9]. Sim​i​lar re​sults were re​ported
in in-vivo nude mice model, in which in​jec​tion of SUM149 cells, sta​!
bly trans​duced with shAhR with ALDH cells, in​hib​ited SOX2
mRNA ex​pres​sion and re​duced tu​mor for​ma​tion [9]. On the other
hand, si​lenc​ing of SOX2 by shSOX2 in murine melanoma B16-F1
cells sig​nif​i​cantly ac​ti​vated AhR ex​pres​sion and nu​clear translo​ca​tion
and in​duced these cells into dor​mancy and pro​lif​er​a​tion ar​rest
through up​reg​u​la​tion of cell cy​cle in​hibitor pro​teins (p27 and p21),
whereas com​plete dele​tion of SOX2 by knock​out caused cells to exit
in​di​cate that AhR is a cen​tral player in main​te​nance of CSCs through
mod​u​la​tion of ABCG2 and SOX2.
3. Epigenetic regulation of cancer and CSCs
The ac​cu​mu​la​tion of ge​netic mu​ta​tions and dis​rup​tion of cel​lu​lar
func​tions are the main rea​sons be​hind can​cer in​duc​tion and pro​gres​!
sion [115]. These mod​i​"​ca​tions fur​ther lead to changes at the hi​s​!
tone and DNA lev​els, also known as the epigenome level which fur​!
ther con​tributes to tu​mor ini​ti​a​tion [115]. Ac​quired or ge​netic epi​!
ge​netic mod​i​"​ca​tions, which could oc​cur to the genome re​gard​less
of the DNA se​quence, in​volve the in​ter​ac​tion with var​i​ous en​zymes
and mol​e​cules [116]. Epi​ge​netic reg​u​la​tion of chro​matin plays an
es​sen​tial role in the con​trol of gene ex​pres​sion through DNA methy​!
la​tion and demethy​la​tion, hi​s​tone mod​i​"​ca​tion, chro​matin post-
trans​la​tional mod​i​"​ca​tions (PTM), and non-cod​ing RNAs reg​u​la​tions
[117]. Since epi​ge​netic reg​u​la​tors are re​versible and af​fected by ex​!
ter​nal fac​tors, they are be​com​ing a promis​ing chemother​a​peu​tic tar​!
get for var​i​ous ther​apy-re​sis​tant can​cers [116].
3.1. DNA Methylation
DNA methy​la​tion is one of the main path​ways in epi​ge​net​ics that
con​trols gene reg​u​la​tion [118]. It in​di​cates the in​clu​sion of a methyl
group to car​bon num​ber "ve in the pyrim​i​dine ring in the CpG din​u​!
cleotide is​lands of the DNA [118]. Si​lenc​ing of tu​mor sup​pres​sor
genes in many types of hu​man can​cers oc​cur via pro​moter methy​la​!
tion. This process is me​di​ated by the ac​ti​va​tion or re​pres​sion of cer​!
tain en​zymes specif​i​cally DNA methyl​trans​ferase and demethy​lase.
DNA methy​la​tion and demethy​la​tion in​duce dif​fer​ent ef​fects at the
tran​scrip​tional level, where hy​per​me​thy​la​tion of the en​hancer or
pro​moter re​gion of DNA leads to gene si​lenc​ing while hy​pomethy​la​!
tion re​sults in up​reg​u​lated gene ex​pres​sion [118]. In can​cer, hy​per​!
me​thy​la​tion of the pro​moter re​gion is the cor​ner stone for in​ac​ti​vat​!
ing genes re​spon​si​ble for reg​u​lat​ing tu​mor sup​pres​sion, cell apop​to​!
sis, and DNA re​pair [119]. Methy​la​tion due to can​cer is known as de
novo methy​la​tion be​cause it ei​ther in​hibits genes that are for​merly
ac​tive in the tis​sue or pre​vents the ac​ti​va​tion of al​ready re​pressed
genes [120].
Sev​eral stud​ies have ex​am​ined the im​pact of DNA methy​la​tion of
cer​tain genes on can​cer and CSCs pro​gres​sion, pro​lif​er​a​tion, and
chemore​sis​tance. One of these genes is CD271, a tu​mor necro​sis fac​!
tor re​cep​tor (TNF) that has an es​sen​tial role in pro​grammed cell
death, cell pro​lif​er​a​tion, and sur​vival [121]. Cells with high CD271
ex​pres​sion have been proven to ex​hibit CSC-like prop​er​ties with high
chemore​sis​tant, tu​mori​genic, and metasta​tic abil​i​ties in hu​man
melanoma tis​sues [121]. It has also been shown that CSC CD271
cells (spher​oids) are more re​sis​tant to can​cer ther​apy com​pared to
CD271- cells [121]. Sev​eral pieces of ev​i​dence sug​gest that CD271
ex​pres​sion is neg​a​tively con​trolled by DNA methy​la​tion. In that, the
in​hi​bi​tion of DNA methyl​trans​ferase I by 5-Aza-2’-de​oxy​cy​ti​dine (5-
aza-CdR) in​creased CD271 ex​pres​sion [121], sug​gest​ing that CSC
fea​tures and chemore​sis​tance are reg​u​lated epi​ge​net​i​cally. Sim​i​larly,
Wang et al., have shown that the chemore​sis​tance of liver can​cer
cells to anti-can​cer agents is at​trib​uted to in​creased Oct4 gene linked
to epi​ge​netic demethy​la​tion of its CpG site [109]. More​over, over​ex​!
pres​sion of CD133  cell sur​face marker in hu​man en​dome​trial can​!
cer tis​sues has shown to play a role in chemore​sis​tance through epi​!

























dor​mancy and re​sume pro​lif​er​a​tion [114]. Fur​ther​more, it is re​!
ported that de​ple​tion of both AhR and ALDH1 in in vitro melanoma
cell lines and in vivo mice model re​duced tu​mor pro​gres​sion,
melanos​phere size, tu​mori​ge​n​e​sis, and or​gan metas​ta​sis via re​duc​ing
the ex​pres​sion of SOX2 [67]. Taken to​gether, these stud​ies clearly​
CpG is shown to be hy​pomethy​lated in the ma​lig​nant tu​mor tis​sues
com​pared to non-ma​lig​nant [122]. Hy​pomethy​la​tion of CD133 is as​!
so​ci​ated with an in​crease in its mRNA and pro​tein ex​pres​sion and lo​!
cal​iza​tion in can​cer​ous com​pared to be​nign tis​sues. Demethy​lat​ing
agent 5-aza-CdR has shown to in​crease CD133 ex​pres​sion [122].
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re​duced in the ma​lig​nant tu​mor ex​press​ing CD133 marker com​pared
to nor​mal en​dometrium cells, which proves that CSCs are epi​ge​net​i​!
cally con​trolled by hy​pomethy​la​tion of the stem​ness mark​ers [122].
In Head and Neck Squa​mous Cell Car​ci​noma (HN​SCC) cell lines, Fu​!
ru​sawa et al., have re​ported that over​ex​pres​sion of CD44  sub​pop​!
u​la​tion, which ex​press higher lev​els of CSC mark​ers, is at​trib​uted to
hy​pomethy​la​tion of sev​eral genes that play a role in tu​mor ini​ti​a​tion
and pro​gres​sion [123].
3.2. Histone Modi#cation
Hi​s​tone mod​i​"​ca​tion oc​curs in the chro​matin ma​te​r​ial that is
mainly com​posed of chro​mo​so​mal DNA and hi​s​tone oc​tamers of four
core hi​s​tone pro​teins, H3, H4, H2A, and H2B [124,125]. Al​ter​ation
in the chro​matin struc​ture is caused by two main mech​a​nisms, ei​ther
through ad​just​ment of N-ter​mi​nal ends of hi​s​tones by chro​matin
mod​i​fy​ing en​zymes at the post-tran​si​tional level, or through al​ter​ing
the in​ter​ac​tion be​tween DNA and hi​s​tones by ATP-de​pen​dent chro​!
matin re​mod​el​ing com​plexes [124]. Some crit​i​cal mod​i​"​ca​tions at
the N-ter​mi​nal are acety​la​tion through hi​s​tone acetyl​trans​ferases
(HATs) and hi​s​tone deacety​lases (HDACs) on the ly​sine residue of
the *-amino group. The methy​la​tion through H3K4 methyl​trans​!
ferases con​trols genes of the de​vel​op​men​tal stage, ubiq​ui​ti​na​tion,
and phos​pho​ry​la​tion, which dras​ti​cally af​fects the gene sta​bil​ity and
chro​mo​so​mal seg​re​ga​tion [124,126]. This ab​nor​mal hi​s​tone mod​i​"​!
ca​tion ini​ti​ates can​cer through dif​fer​en​tial gene ex​pres​sion and onco​!
gene reg​u​la​tion [124].
Yan et al., stud​ied the ef​fect of epi​ge​netic fac​tors on chemore​sis​!
tant AML cells char​ac​ter​ized by CD123 /CD47  and demon​strated
that in​hi​bi​tion of HDAC by Ro​midepsin re​sults in in​duc​tion of apop​!
to​sis and cell cy​cle ar​rest of chemore​sis​tant cells in vitro and
xenograft mouse model of AML [127]. More​over, HDAC in​hibitors
showed a syn​er​gis​tic ef​fect when given as a com​bi​na​tion with
chemother​apy drug Ara-C [127]. In breast can​cer, Darvin et al.,
have shown that breast CSCs of MCF-7 and BT-549 ex​press high
level of PD-L1 which is mainly me​di​ated through hy​pomethy​la​tion
of its pro​moter re​gion and ac​tive hi​s​tone mark​ers, in​clud​ing
H3K9me3 and H3K27me3 [128]. These re​sults were fur​ther con​!
"rmed by the over-ex​pres​sion of TET3 and down​reg​u​la​tion of DN​!
MTs, the en​zymes re​spon​si​ble for ac​tive demethy​la​tion [128]. Fur​!
ther​more, it has been re​ported that sev​eral breast can​cer cells (T47D,
MDA-MB-231, MDA-MB-468, and MCF-7) ex​press high lev​els of
HDAC-3 which is pos​i​tively cor​re​lated with ad​vanced breast can​cer
TNM stage [129]. On the other hand, can​cer as​so​ci​ated "​brob​lasts
(CAF), a me​di​a​tor of tu​mor pro​gres​sion and metas​ta​sis, ex​press
higher lev​els of HDAC-6, caus​ing im​muno​sup​pres​sion and chemore​!
sis​tance [130]. In ovar​ian can​cer, it was re​ported that met​formin in​!
hibits ovar​ian ade​no​car​ci​noma cell (SKOV3) and ovar​ian clear cell
car​ci​noma cells (ES2) pro​lif​er​a​tion and in​duces apop​to​sis through
de​creas​ing hi​s​tone H3 ly​sine 27 trimethy​la​tion H3K27me3 [131].
More​over, some stud​ies on ovar​ian can​cer have shown that hi​s​tone
mod​i​"​ca​tion is re​spon​si​ble for the loss of tu​mor necro​sis fac​tor
mem​bers such as FAS and hence cause chemore​sis​tance. In that, the
level of acety​lated hi​s​tone H3 as​so​ci​ated with FAS pro​moter was
dras​ti​cally de​creased in the chemore​sis​tant A2780-AD cells com​!
pared to nor​mal ovar​ian cells, whereas, HDAC-1 was el​e​vated in
A2780-AD cells [132]. In​hi​bi​tion of the HDAC-1 caused a sig​nif​i​cant
genic miRNA in colon CSCs [133]. These stud​ies sug​gest that tar​get​!
ing HDAC could be a po​ten​tial tar​get for chemo​pre​ven​tion and ther​!
apy.
3.3. MicroRNAs
Mi​croR​NAs (miR​NAs) are small non-cod​ing RNA re​gions, lo​cal​!
ized in the nu​cleus and cy​to​plasm of the cell [134,135]. Once de​vel​!
oped, the miR​NAs trans​late into RNA-in​duced si​lenc​ing com​plexes
(RISC) con​trol​ling the gene ex​pres​sion at the post-tran​scrip​tional
level by bind​ing to the 3’-un​trans​lated re​gion (3’-UTR) of the mRNA
[134,135]. These miR​NAs con​trol crit​i​cal cell path​ways such as cell
mat​u​ra​tion, growth, di​vi​sion, and sur​vival, and thus they are con​sid​!
ered to be a po​ten​tial ther​a​peu​tic tar​get [135]. The dys​reg​u​la​tion of
miR​NAs has been as​so​ci​ated with the patho​gen​e​sis of hu​man dis​!
eases in​clud​ing can​cer. In can​cer, the epi​ge​netic reg​u​la​tion of
miRNA oc​curs through DNA methy​la​tion, hi​s​tone mod​i​"​ca​tion, and
gene si​lenc​ing [134]. Stud​ies have shown that miRNA genes are
most si​lenced af​ter DNA methy​la​tion in the CpG is​lands of the pro​!
moter re​gion, whereas dis​tant CpG is​lands lo​cated away from
miRNA, func​tion as en​hancers to reg​u​late the miRNA gene ex​pres​!
sion [136]. More​over, the hy​droxy-methy​lated cy​to​sine formed dur​!
ing the ac​tive demethy​la​tion of the CpG tran​scripts acts as tran​scrip​!
tion en​hancers of some miRNA [136]. Fur​ther​more, the miRNA ex​!
pres​sion is ei​ther en​hanced or in​hib​ited by post-tran​scrip​tion hi​s​tone
mod​i​"​ca​tions de​pend​ing on whether the N-ter​mi​nal was methy​lated
or acety​lated [136].
The in​volve​ment of miRNA dys​reg​u​la​tion in CSCs and chemore​!
sis​tance has not been thor​oughly in​ves​ti​gated. Breast CSCs ex​press​!
ing el​e​vated lev​els of stem cell sur​face mark​ers CD44 /CD24- and
SP cells have been shown to ex​press re​duced lev​els of miR-34a, a tu​!
mor sup​pres​sor miRNA that tar​gets NOTCH path​way [137]. The si​!
lenc​ing ef​fect of miR-34 on Notch path​way and CSCs was sup​ported
by the ob​ser​va​tions that restora​tion of the miR-34a level by trans​!
fect​ing breast can​cer re​sis​tant cells with miR-34a mim​ics, re​duces
mam​mos​phere for​ma​tion, CD44 /CD24- pop​u​la​tion, Notch ex​pres​!
sion lev​els, and CSC self-re​newal ca​pac​ity [137]. This over​ex​pres​!
sion of miR-34a was as​so​ci​ated with a de​crease in tu​mor for​ma​tion
and in​crease in sen​si​tiv​ity to chemother​a​peu​tic agents in nude mice
can​cer model [137]. These re​sults sug​gest that miR-34a sup​presses
CSC self-re​newal ca​pac​ity through tar​get​ing Notch path​way. The
miR​NAs 451, 144, and 139-5p have been re​ported to neg​a​tively
mod​u​late CSC fea​tures in col​orec​tal can​cer. In that, col​orec​tal CSCs
char​ac​ter​ized by el​e​vated lev​els of mark​ers such as,
CD44 /CD133 , Ep​Cam, CD166, and CD24 ex​pressed low lev​els of
miR-451 [138] or miR-139-5p [139] com​pared to ad​her​ent col​orec​!
tal can​cer cells. The down​reg​u​la​tion of miR-451 or miR-139-5p is
cor​re​lated to tu​mor ag​gres​sive​ness, chemore​sis​tance, and higher risk
of re​lapse [138,139]. Fur​ther​more, over​ex​pres​sion of miR-451 in​!
hibits spheres pro​duc​tion and colony for​ma​tion abil​i​ties, and in​!
creases sen​si​tiv​ity to sev​eral chemother​a​peu​tic agents through
down​reg​u​la​tion of drug-ef​#ux genes, ABCB1 [138] and NOTCH1 ex​!
pres​sion [139]. In pan​cre​atic can​cer, Cio% et al., have demon​strated
that can​cer re​cur​rence and chemore​sis​tance are con​trolled by epi​ge​!
netic reg​u​la​tors in which, pan​cre​atic CSC spheres show down​reg​u​la​!
tion of the miR-17-92, miR-513a-5p, and miR-513b [140]. This tu​!

















in​crease of FAS ex​pres​sion in A2780-AD cells [132], in​di​cat​ing that
epi​ge​netic changes reg​u​lated by hi​s​tone mod​i​"​ca​tion con​tributed to
chemore​sis​tance due to the loss of tu​mor sup​pres​sor genes [132].
Kim and co-work​ers have shown that the an​ti​cancer ef​fect of "-
carotene against col​orec​tal can​cer cells is me​di​ated by in​creas​ing the
hi​s​tone acety​la​tion of H3 and H4 through down​reg​u​lat​ing tu​mori
that knock​down of miR17-92 re​sulted in up​reg​u​la​tion of CD133 CSC
sur​face marker, ABC trans​porters, and the abil​ity of can​cer cells self-
re​newal, as ev​i​denced by sphere for​ma​tion [140]. Sim​i​larly, blad​der
CSCs with high ALDH  and tu​mori​genic ca​pac​ity were in​versely
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4. Epigenetic regulation of AhR expression and function in
cancer
Ac​ti​va​tion of the AhR causes a crosstalk with coac​ti​va​tor com​!
plexes in​side the nu​cleus to in​duce epi​ge​netic mod​i​"​ca​tions at the
pro​moter and en​hancer re​gions of tar​get genes, in​clud​ing CYP1A1,
CYP1B1, and CYP1A2. In this sec​tion, we re​view the ef​fects of DNA
methy​la​tion, hi​s​tone mod​i​"​ca​tion, and miRNA on the ex​pres​sion,
func​tion, and ac​tiv​ity of AhR, CYP1A1, CYP1B1, and CYP1A2 genes
in dif​fer​ent tis​sues and cell lines.
4.1. AhR
DNA methy​la​tion of the pro​moter re​gion of genes per​mit gene si​!
lenc​ing by pre​vent​ing the re​cruit​ment of tran​scrip​tion fac​tors to the
con​sen​sus se​quence [142]. The stud​ies in​volv​ing iso​la​tion and char​!
ac​ter​i​za​tion of AhR gene demon​strate that the pro​moter of AhR gene
is a GC rich re​gion which lacks CCAAT and TATA box and has a
min​i​mum of four func​tional speci​"city pro​tein 1 (SP1)-like bind​ing
sites [143]. These CpG is​lands are eas​ily methy​lated which leads to
gene sup​pres​sion. AhR is found to be hy​per​me​thy​lated in about 33%
of pri​mary hu​man acute lym​phoblas​tic leukemia (ALL) which sug​!
gests that the tu​mor sup​pres​sion role of this re​cep​tor is dis​rupted in
these can​cers [144]. The sup​pres​sion of AhR through methy​la​tion in
the pro​moter re​gion has been ob​served in dif​fer​ent can​cer cell lines
such as chronic myeloid leukemia (K562) and acute lym​phoblas​tic
leukemia (REH) cells [144]. In that, treat​ment of AhR  ex​press​ing
ALL cells (REH) with DNA methy​la​tion in​hibitor, 5-aza-CdR, sig​nif​i​!
cantly in​creased the mRNA and pro​tein ex​pres​sion of AhR. This in​!
hibitory ef​fect of DNA methy​la​tion on AhR ex​pres​sion is at​trib​uted
to the im​paired bind​ing of sp1 tran​scrip​tion fac​tor to AhR pro​motr
[144]. On the other hand, in mouse liver, AhR ac​ti​va​tion by TCDD
caused an AhR-de​pen​dent CpG demethy​la​tion and re​cruit​ment of
DNA gly​co​sy​lase at CYP1A1 pro​motr [145].
Hi​s​tone acety​la​tion plays a role in the tran​scrip​tional ac​tiv​ity of
AhR gene pro​moter. The con​sti​tu​tive ex​pres​sion of AhR is in​creased
by the HDAC in​hibitors, bu​tyrate or tri​cho​statin A (TSA), in wild-
type and AhR-de​"​cient mouse he​patoma He​pa1 cells, whereas the
ac​tiv​ity of AhR is de​creased upon the treat​ment with HDAC [143].
In ad​di​tion, it has been demon​strated that in​creased ex​pres​sion of
AhR in hu​man breast can​cer MCF-7 cells is at​trib​uted to de​creased
hi​s​tone trimethy​la​tion, but not DNA methy​la​tion [146]. In hu​man
he​pa​to​cel​lu​lar car​ci​noma HepG2 cells, it has been re​ported that in​hi​!
bi​tion of hi​s​tone deacety​la​tion by TSA in​creases the AhR-XRE lu​!
ciferase ac​tiv​ity [147]. Ad​di​tion​ally, AhR ac​ti​va​tion is also as​so​ci​!
ated with re​duced ex​pres​sion of cer​tain miR​NAs that are be​lieved to
play a role in can​cer. AhR is im​pli​cated in re​duc​ing the lev​els of
miR-96 which plays a role in tu​mor pro​gres​sion through the sup​pres​!
sion of FOX​O3a, a tu​mor sup​pres​sor tran​scrip​tion fac​tor that is fre​!
quently in​ac​ti​vated in can​cer [148–150].
4.2. CYP1A1
Epi​ge​netic reg​u​la​tion of CYP1A1 has been shown to al​ter the
func​tion and ex​pres​sion of sev​eral genes and tran​scrip​tion fac​tors
that are known to play a cru​cial role in the de​vel​op​ment of dis​eases.
treat​ment in mouse liver causes AhR de​pen​dent demethy​la​tion in
two CpGs in CYP1A1 prox​i​mal pro​moter which sug​gests that AhR
ag​o​nists tran​scrip​tion​ally ac​ti​vates CYP1A1 in mouse liver [145].
These stud​ies col​lec​tively sug​gest a neg​a​tive im​pact of the DNA
methy​la​tion on the AhR/​CYP1A1 and XRE func​tion.
Hi​s​tone mod​i​"​ca​tions at the CYP1A1 pro​moter re​gion has also
been shown to per​mit the in​duc​tion of CYP1A1 ex​pres​sion. Chro​!
matin im​muno​pre​cip​i​ta​tion ex​per​i​ments re​vealed that the hu​man
prostate cells PWR-1E and RWPE-1 ex​hibit trimethyl hi​s​tone H3 ly​!
sine 4 which is a marker of ac​tive CYP1A1 gene, whereas the can​cer​!
ous LNCaP cells lack this hi​s​tone mod​i​"​ca​tion which in​di​cates the
im​por​tance of hi​s​tone mod​i​"​ca​tion in the ex​pres​sion of CYP1A1
[153]. In ad​di​tion, the ac​ti​va​tion of the AhR by TCDD en​hances the
trimethy​la​tion of H4Ac and H3K4 in the pro​moter re​gion of CYP1A1
in mouse liver, whereas de​creases re​pres​sive marker, H4K20me3
[145]. Specif​i​cally, it was re​ported that in​hi​bi​tion of HDAC1 ei​ther
ge​net​i​cally or by us​ing chem​i​cal in​hibitor TSA, in​creased the ex​pres​!
sion of CYP1A1 and AhR func​tion in hu​man neu​rob​las​toma [155],
breast MCF-7, and cer​vi​cal HeLa [154], HepG2 [147], and mouse
he​patoma He​pa1 [156] cells. Us​ing chro​matin im​muno​pre​cip​i​ta​tion
(ChIP) as​say, Jin and co-work​ers have demon​strated that treat​ment
of Caco-2 cells with bu​tyrate, a HDAC in​hibitor, re​cruited AhR and
the poly​merase II and en​hanced H3K47Ac and H3K9Ac on CYP1A1
pro​motr [157]. Al​to​gether, these stud​ies re​veal the im​por​tance of hi​!
s​tone mod​i​"​ca​tions in the ex​pres​sion of CYP1A1 gene.
The post​trans​la​tional ex​pres​sion of the CYP1A1 was shown to be
reg​u​lated by miR​NAs, par​tic​u​larly miR-125b-2, miR-488, miR-657,
miR-892a, miR-511, and miR-626 [158,159]. For ex​am​ple, over​ex​!
pres​sion of miR-892a in hu​man breast can​cer MCF-7 cells caused
CYP1A1 pro​tein in​hi​bi​tion, which is in agree​ment with the ob​ser​va​!
tions that BaP, a po​tent CYP1A1 in​ducer, de​creased the miR-892a
ex​pres​sion [159]. In ad​di​tion, Rieger et al., have also shown that
miR-21, miR-132 and miR-142-3p neg​a​tively reg​u​lated the ex​pres​!
sion of CYP1A1 in hu​man liver tis​sues [160] but not in hu​man he​pa​!
to​cyte He​paRG cells [161]. In​ter​est​ingly, the bind​ing sites of these
miRNA have been iden​ti​"ed on CYP1A1 mRNA [162,163], sug​gest​!
ing a reg​u​la​tory role for the miRNA in CYP1A1 reg​u​la​tion.
4.3. CYP1B1
The CYP1B1 ex​pres​sion has been found to be lower in he​patic
can​cer, HepG2 cell line ow​ing to the CYP1B1 pro​moter methy​la​tion.
In hu​man liver can​cer HepG2 cells [164] and col​orec​tal can​cers
[165], it was re​ported that the CpG din​u​cleotides within the CpG is​!
land en​com​pass​ing CYP1B1 pro​motr are fully methy​lated, whereas
par​tially methy​lated in the en​hancer re​gion. This hy​pomethy​la​tion
of the CYP1B1 in the en​hancer al​lows XRE/​ARNT dimer​iza​tion with
sub​se​quent CYP1B1 in​duc​tion [164]. CYP1B1 pro​moter also con​!
tains se​quence for the Sp1 tran​scrip​tion fac​tor bind​ing that par​tic​i​!
pates in the reg​u​la​tion of CYP1B1. There​fore, the changes in DNA
methy​la​tion in the CpG mo​tif af​fect the bind​ing and ac​tiv​ity of these
tran​scrip​tion fac​tors which sub​se​quently af​fect CYP1B1 ex​pres​sion
[166]. Sim​i​lar to CYP1A1, the CYP1B1 in​ducibil​ity in HepG2 cells is
in​duced by the demethy​lat​ing agent 5-aza-CdR in hu​man he​patoma
HepG2 [164] and col​orec​tal SW48 and Caco-2 [165] cells. In hu​!
man prostate can​cer, it has been shown that in​duc​tion of CYP1B1
low
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In can​cer, it has been shown that DNA methy​la​tion of CYP1A1 en​!
hancer re​gion blocked the AhR ac​ti​va​tion and CYP1A1 in​duc​tion by
the AhR in​ducer 3-MC in rab​bit nor​mal lung R9ab [151] and mouse
he​patoma [152] cell lines. Whereas, in​hi​bi​tion of DNA methy​la​tion
us​ing 5-aza-CdR sig​nif​i​cantly in​creased the in​duc​tion of CYP1A1 ex​!
pres​sion in can​cer​ous, but not in non​cancer​ous, hu​man prostate
LNCaP cells [153], hu​man he​patoma HepG2 [147], hu​man breast
MCF-7 and cer​vi​cal ade​no​car​ci​noma cells [154]. Ad​di​tion​ally, TCDD​
pro​tein and mRNA is reg​u​lated by the CpG hy​pomethy​la​tion of the
pro​moter re​gion [58], in​di​cat​ing that hy​pomethy​la​tion of CYP1B1
pro​moter plays a sig​nif​i​cant role in in​creas​ing the CYP1B1 ex​pres​!
sion in can​cer. On the con​trary, up​reg​u​la​tion of CYP1A1 mRNA in
long-term es​tro​gen ex​posed MCF-7 cells was re​sulted from CpG
methy​la​tion of the CYP1B1 pro​moter [146].
Beedana​gari and co-work​ers found through ChIP analy​sis that in​!
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ly​sine 4 (me3H3K4), acety​la​tion of hi​s​tone H4 (AcH4), and acety​la​!
tion of hi​s​tone H3 at ly​sine 9 and 14 (AcH3K9 and AcH3K14) were
lesser in HepG2 cells than MCF-7 cells both be​fore and af​ter dioxin
treat​ment. Thus, dioxin in​duces hi​s​tone mod​i​"​ca​tions at CYP1A1
and CYP1B1 pro​moter re​gions in MCF-7 cells lead​ing to in​creased
their ex​pres​sion [164]. It was re​ported that HDAC in​hibitors, TSA or
val​proic acid, de​creased the mRNA ex​pres​sion of CYP1B1 in neu​rob​!
las​toma UKF-NB-3 and -4 cell lines [151], whereas in​creased the
AhR-me​di​ated in​duc​tion of the CYP1B1 and AhRR in Caco-2 cells
[153], sug​gest​ing a cell-spe​ci"c mech​a​nism. Tsuchiya et al., have
shown that the post​tran​scrip​tional reg​u​la​tions of CYP1B1 in MCF-7
[167] and HepG2 [168] cells were neg​a​tively con​trolled by miR-
27b, where its recog​ni​tion el​e​ment (MRE27b) was iden​ti​"ed in
CYP1B1 mRNA. Fur​ther​more, si​lenc​ing of miR-27 suc​cess​fully re​!
stored the en​zy​matic ac​tiv​ity and pro​tein ex​pres​sion of CYP1B1
[167]. This sug​gests that de​creased ex​pres​sion of miR-27 could be
one of the mech​a​nisms re​spon​si​ble for the higher ex​pres​sion of
CYP1B1 in can​cer cells.
4.4. CYP1A2
Ex​pres​sion of CYP1A2 is af​fected epi​ge​net​i​cally in a tis​sue-spe​!
ci"c man​ner. CpG site on the pro​mo​tor re​gion of CYP1A2 was hy​!
pomethy​lated in murine liver com​pared to the lung and kid​ney
[169]. CpG hy​per​me​thy​la​tion of the pu​ta​tive GC box on CYP1A2
pro​moter in hu​man liver HepG2 cells and tis​sues showed sig​nif​i​cant
in​verse reg​u​la​tion of its mRNA ex​pres​sion [170,171], whereas the
en​zy​matic ac​tiv​ity showed in​ter-in​di​vid​ual vari​a​tion [170]. In that,
the in​hi​bi​tion of DNA methyl​trans​ferases by 5-aza-CdR in​duced
CYP1A2 tran​script lev​els in hu​man em​bry​onic stem cell-de​rived he​!
pa​to​cytes, hESC-Hep [172]. In he​patoma He​pa1c1c7 cells, non-ex​!
pres​sion of CYP1A2 is at​trib​uted to the hy​per​me​thy​la​tion of its CpG
site, how​ever, in mouse pri​mary he​pa​to​cyte cul​ture, demethy​la​tion
with 5-aza-CdR did not in​duce CYP1A2 [169]. Hi​s​tone mod​i​"​ca​tion
has been re​ported to reg​u​late CYP1A2 ex​pres​sion in dif​fer​ent cells.
In this con​text, it was demon​strated that in​hi​bi​tion of HDAC by TSA
or val​proic acid sig​nif​i​cantly in​duced CYP1A2 ex​pres​sion and pro​!
moter ac​tiv​ity in he​pa​to​cel​lu​lar car​ci​noma Hep3B [173], hu​man
breast can​cer MCF-7 and cer​vi​cal can​cer HeLa cells [154].
In ad​di​tion to ge​netic poly​mor​phisms and tran​scrip​tion fac​tors,
the ex​pres​sion of CYP1A2 is in​#u​enced by the post-tran​scrip​tional
reg​u​la​tion of miR​NAs. Pa​tients with steroid-in​duced avas​cu​lar necro​!
sis of femoral head (SANFH) char​ac​ter​ized by low ex​pres​sion lev​els
of miR-320 ex​hibit high CYP1A2 ex​pres​sion and en​zy​matic ac​tiv​ity,
sug​gest​ing a neg​a​tive reg​u​la​tion [174]. In non-can​cer liver tis​sues,
the ex​pres​sion of hsa-miR-221-5p and hsa-miR-132-5p were in​!
versely cor​re​lated with the ex​pres​sion of CYP1A2 which in​di​cate a
pos​si​ble anti-can​cer po​ten​tial of these miR​NAs [175–177]. More​!
over, hsa-miR-132-5p in​ter​acts with CYP1A2 within the tran​script of
CYP1A2 3’-UTR through its cog​nate tar​get and is con​sid​ered as
CYP1A2 reg​u​la​tor [177]. Ad​di​tion​ally, the trans​fec​tion of hsa-miR-
132-5p in he​patic stem cells He​paRG and hu​man he​patoma cell
lines, Huh-7 and HepG2, sig​nif​i​cantly re​duced basal and lan​so​pra​!
zole-in​duced CYP1A2 mRNA and pro​tein ex​pres​sion [177], sug​gest​!
ing that tar​get​ing hsa-miR-132-5p could be a novel drug tar​get for
tone mod​i​"​ca​tions, and miR​NAs are be​lieved to play a role in the
main​te​nance of CSCs prop​er​ties [179,180]. Al​though the epi​ge​netic
reg​u​la​tion of CSCs has been re​viewed be​fore [181], the cur​rent re​!
view will be the "rst to ad​dress the role and im​pact of the epi​ge​netic
reg​u​la​tion of AhR/​CYP1 on CSCs. In gen​eral, epi​ge​netic reg​u​la​tions
of the AhR and down​stream genes, par​tic​u​larly CYP1A1 and
CYP1B1, have been shown to mod​u​late the pro​lif​er​a​tion of can​cer
cells and the de​vel​op​ment and chemore​sis​tance of CSCs through the
mod​u​la​tion of sev​eral tran​scrip​tion fac​tors and reg​u​la​tory genes. In
this sec​tion, we high​light the most com​mon mech​a​nisms of epi​ge​!
netic reg​u​la​tion of CSCs by AhR/​CYP1 path​ways (Fig. 2) in sev​eral
can​cer types which are sum​ma​rized in Table 2.
5.1. Breast Cancer
Breast can​cer is the most ex​ten​sively stud​ied type of can​cer for
the in​ves​ti​ga​tion of the epi​ge​netic reg​u​la​tions of CSCs by AhR/​CYP1
path​way. In gen​eral, AhR/​CYP1A1 can reg​u​late breast CSCs epi​ge​!
net​i​cally through mod​u​lat​ing the ex​pres​sion and ac​tiv​ity of four ma​!
jor genes: breast can​cer gene 1 (BR​CA1), p53, SOX, and "-catenin.
Breast can​cer gene 1 (BR​CA1) is a tu​mor sup​pres​sor gene that is
known to play a vi​tal role in re​pair​ing DNA dam​age and hence the
ge​nomic sta​bil​ity. BRCA genes are mainly ex​pressed in the breast tis​!
sues and hence, ab​nor​mal reg​u​la​tion of BRCA genes ei​ther epi​ge​net​i​!
cally or mu​ta​tion​ally is known to in​crease the risk of breast can​cer.
In that, BR​CA1 down-reg​u​la​tion in breast can​cer cells is ob​served to
in​crease CSC pop​u​la​tions and char​ac​ter​is​tics, whereas its up-reg​u​la​!
tion sup​presses CSC fea​tures such as colono​genic po​ten​tial, CD44 ex​!
pres​sion, and ALD​H1A1 ac​tiv​ity [182]. Re​cent stud​ies on breast can​!
cer have re​ported the im​pact of epi​ge​n​e​sis on the in​ter​ac​tion be​!
tween BRCA genes and AhR [183,184]. In that, BR​CA1 gene is sub​!
jected to epi​ge​netic mod​i​"​ca​tions and si​lenc​ing by AhR and reg​u​!
lated genes which caused gene sup​pres​sion in spo​radic breast tu​mor
[185]. The con​sti​tu​tively high AhR ex​pres​sion in hu​man TNBC tu​!
mor tis​sue is as​so​ci​ated with BR​CA1 pro​moter CpG methy​la​tion,
which is higher in TNBC than lu​mi​nal A, lu​mi​nal B, and HER2 pos​i​!
tive breast can​cer, sug​gest​ing that AhR/​BRCA genes ex​pres​sion
could be a mol​e​c​u​lar marker for TNBC [183]. Ad​di​tion​ally, the in​!
tro​duc​tion of AhR in​ducer, DMBA, in rat mam​mary tu​mor in​creased
BR​CA1 CpG methy​la​tion, CYP1A1 and CYP1B1 ex​pres​sion, and cell
pro​lif​er​a​tion mark​ers Cc​nd1 and Cdk4, whereas treat​ment of es​tro​!
gen re​cep​tor $-neg​a​tive hu​man spo​radic breast can​cer UACC-3199
cells with $-NF, an AhR an​tag​o​nist, was re​ported to par​tially res​cue
BR​CA1 ex​pres​sion [183]. At the in​ducible level, ac​ti​va​tion of AhR
by TCDD in hu​man breast can​cer MCF-7 cells per​mits the as​so​ci​a​tion
of DNA methyl​trans​ferase-1 (DN​MT1), mono-methy​lated-H3K9, and
methyl-bind​ing do​main pro​tein-2 (MBD-2) with BR​CA1 pro​moter
[185]. This ef​fect of AhR on BR​CA1 hy​per​me​thy​la​tion was re​versed
by AhR in​hi​bi​tion ei​ther us​ing siRNA or chem​i​cal in​hibitor, resver​a​!
trol [185]. Al​though resver​a​trol has mul​ti​ple tar​gets other than AhR,
the siRNA con​"rms the in​volve​ment of AhR in BR​CA1 hy​per​me​thy​!
la​tion. Ex​po​sure of rats to TCDD, a strong AhR ac​ti​va​tor and
CYP1A1 in​ducer, in utero, re​vealed an as​so​ci​a​tion be​tween hy​per​me​!
thy​la​tion of BR​CA1 gene pro​moter in breast tis​sues and in​ci​dence of
breast can​cer in adult​hood. In MCF-7 breast can​cer cells, the BR​CA1
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cell ex​press​ing CYP1A2-in​duced chemother​apy re​sis​tance.
5. Mechanisms of the epigenetic regulations of CSCs by the AhR
and regulated genes
Epi​ge​netic dys​reg​u​la​tion in var​i​ous types of can​cer has been
shown to play crit​i​cal roles in pro​duc​ing CSCs and tu​mori​ge​n​e​sis via
mod​u​lat​ing the ex​pres​sion of tu​mor sup​pres​sor and dif​fer​en​ti​a​tion
genes [178]. The si​lenc​ing of these genes con​tribute to the for​ma​!
tion of CSCs in a tu​mor pop​u​la​tion, there​fore, DNA methy​la​tion, hi​s
re​pres​sion also re​sults from in​creased BR​CA1 gene oc​cu​pancy by
AhR and HDAC1 and re​duced as​so​ci​a​tion of hi​s​tone acetyl​trans​!
ferase (HAT) p300 [186], AcH3K9, acety​lated H4 (H4Ac) [185],
and SRC-1 with BR​CA1. In ad​di​tion, AhR also con​fers other epi​ge​!
netic al​ter​ations that lead to BR​CA1 re​pres​sion such as deacety​la​tion
of H3K9; el​e​vated lev​els of DN​MT1, DN​MT3a, DN​MT3b, H3K9me3,
and MBD-2; and CpG hy​per​me​thy​la​tion [185,187]. There​fore, the
ac​ti​va​tion of AhR in​duces epi​ge​netic si​lenc​ing of tu​mor sup​pres​sor,
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Fig. 2. Schematic di​a​gram sum​ma​riz​ing the mol​e​c​u​lar mech​a​nisms of epi​ge​netic reg​u​la​tion of the CSCs by AhR and the tar​get genes.
Sev​eral stud​ies have re​ported that BR​CA1 se​lec​tively coac​ti​vates
p53, a tu​mor sup​pres​sor gene, to​wards DNA re​pair and cell cy​cle ar​!
rest in breast can​cer [188]. Im​paired p53 ex​pres​sion and func​tion in
dif​fer​ent breast can​cer mod​els has been re​ported to in​crease CSC ex​!
pan​sion and chemore​sis​tance through in​duc​tion of mul​tidrug-re​sis​!
tant genes [189,190]. Ac​ti​va​tion of p53 by CP-31398 and PRIMA in
breast can​cer cell lines (MDA-MB-231, SUM149) in​hib​ited the
ALDH  cells and the sphere for​ma​tion abil​ity [190,191]. The epi​ge​!
netic reg​u​la​tion of p53 by AhR in breast can​cer has not been well
stud​ied and war​rant fur​ther in​ves​ti​ga​tion. Locke and his team have
demon​strated that in​duc​tion of car​cino​gen​e​sis in mam​mary ep​ithe​!
lial cells by AhR ac​ti​va​tion was as​so​ci​ated with in​creased hy​per​me​!
thy​la​tion of p53 bind​ing sites in EPHB3 and TRIM6 re​sult​ing in re​!
pres​sion of the tu​mor sup​pres​sor hsa-miR-143/​145 clus​ter and
dereg​u​la​tion of p53 tar​get genes, MDM2 and CD​KN1A [192]. Sim​i​!
larly, AhR ac​ti​va​tion and CYP1 in​duc​tion by TCDD in hu​man ker​!
atinocyte has shown to in​crease p53 methy​la​tion re​sult​ing in gene si​!
lenc​ing [193]. This AhR-in​duced hy​per​me​thy​la​tion of p53 tar​get
genes re​sulted in loss of cell cy​cle con​trol and breast car​cino​gen​e​sis
[192,194].
SRY-box tran​scrip​tion fac​tor 4 (SOX4) is a pro-metasta​tic me​di​a​!
tor that is highly ex​pressed in dif​fer​ent types of can​cer, in​clud​ing
breast can​cer. Over​ex​pres​sion of SOX4 is as​so​ci​ated with in​creased
mal breast cells har​bour more miR-335 com​pared to spo​radic breast
can​cer cells, whereas in TNBC tis​sues, the ex​pres​sion of miR-335 is
re​duced com​pared to its ad​ja​cent tis​sues, which in​creases the
chemore​sis​tance of these cells to dox​oru​bicin, pa​cli​taxel, and cis​!
platin [197]. Fur​ther​more, it was re​ported that treat​ment of breast
can​cer MDA-MB-231 and T47D cells with AhR/​CYP1A1 ac​ti​va​tor
such as TCDD sup​presses SOX4 ex​pres​sion through an AhR-me​di​ated
tran​scrip​tional ac​ti​va​tion of miR-212/​132 clus​ter [198]. On the
other hand, it has been shown that in​hi​bi​tion of AhR/​CYP1A1 by
resver​a​trol, a well-known AhR an​tag​o​nist, in​duced hy​pomethy​la​tion
and ac​ti​va​tion of SOX17, a tu​mor sup​pres​sor gene, in TNBC MDA-
MB-231 cells [199].
Wnt/"-catenin is an im​por​tant reg​u​la​tor of can​cer de​vel​op​ment
and ini​ti​a​tion. Ac​ti​va​tion of AhR and CYP1A1 by DMBA has been re​!
ported to in​crease the ex​pres​sion and ac​tiv​ity of "-catenin in hu​man
breast can​cer MCF-7 cells, which was as​so​ci​ated with in​creased CSC
prop​er​ties [200]. Epi​ge​netic study in​ves​ti​gat​ing the mech​a​nism of "-
catenin ac​ti​va​tion by AhR in​ducer BaP has shown an in​crease in the
ex​pres​sion of HDAC-6 in TNBC MDA-MB-231 cells, which in turn
con​tributes to the nu​clear for​ma​tion of "-catenin-LEF1/​TCF4 tran​!
scrip​tional com​plex that sub​se​quently par​tic​i​pates in tran​scrip​tional
ac​ti​va​tion of its tar​get gene, c-Myc [201]. More​over, in breast ep​!














breast CSC fea​tures such as EMT and CD44 /CD24  pop​u​la​tion
[195]. The AhR-me​di​ated epi​ge​netic reg​u​la​tion of SOX4 oc​curs
through the mod​u​la​tion of sev​eral miR​NAs, such as miR-335 and
miR-212/​132. In that, ac​ti​va​tion of AhR/​CYP1A1 path​way by TCDD or
6-methyl-1,3,8-trichlorodiben​zo​fu​ran (MCDF) in hu​man breast can​cer
BT474 and MDA-MB-231 cells caused in​hi​bi​tion of the mRNA and
pro​tein ex​pres​sion of SOX4 through the in​duc​tion of miR-335, an ef​!
fect that was blocked by AhR si​lenc​ing, sug​gest​ing an in​ter​ac​tion be​!
tween AhR and miR-335 for the reg​u​la​tion of SOX4 [196]. The nor
pro​lif​er​a​tion due to methy​la​tion of CpG of Wnt in​hibitory fac​tor 1
(WIF-1), which en​codes in​hibitor of Wnt path​way, re​sult​ing in ac​ti​!
va​tion of Wnt/"-catenin path​way [202]. An​other mech​a​nism of AhR
epi​ge​netic reg​u​la​tion of c-Myc ex​pres​sion is through the mod​u​la​tion
of miR-494 in es​tro​gen re​cep​tor MCF-7 cells [203]. Ac​ti​va​tion of "-
catenin and c-Myc is as​so​ci​ated with in​creased mam​mos​phere for​ma​!
tion, per​cent​age of SP, and ALDH  cells [200]. To ex​plore the im​!
pact of epi​ge​n​e​sis in the crosstalk be​tween AhR and es​tro​gen re​cep​!
tor, En​glert and co-work​ers have demon​strated that long-term es​tro​!
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through hi​s​tone mod​i​"​ca​tion. More​over, de​creased trimethy​la​tion of
hi​s​tone 3 at ly​sine 27 was par​tic​u​larly seen at the prox​i​mal pro​moter
of AhR in LTEE MCF-7 cells. The pro​moter of AhR in LTEE MCF-7
cells is not as​so​ci​ated with the mark​ers of epi​ge​netic si​lenc​ing which
caused in​creased ex​pres​sion of AhR con​tribut​ing to breast car​cino​!
[206,207]. In that, si​lenc​ing of BR​CA1 gene by hy​per​me​thy​la​tion of
its pro​moter was demon​strated in pri​mary ovar​ian car​ci​noma. BR​!
CA1 pro​moter hy​per​me​thy​la​tion has been con​"rmed as a fac​tor for
BR​CA1 gene in​ac​ti​va​tion in ovar​ian can​cer pa​tients and sev​eral














gen​e​sis [146]. These stud​ies demon​strate the dif​fer​en​tial role of AhR
in breast can​cer as it par​tic​i​pates in var​i​ous epi​ge​netic mod​i​"​ca​tions.
5.2. Endometrial and Ovarian Cancer
Ovar​ian can​cer is the most lethal out of all gy​ne​co​log​i​cal ma​lig​!
nan​cies and stands fourth in terms of can​cer re​lated deaths glob​ally.
Ovar​ian can​cer is char​ac​ter​ized by non​spe​ci"c and vague symp​toms
that make two-third of pa​tients di​ag​nosed only at late-stages lead​ing
to poor prog​no​sis (II-IV) [204]. Small tu​mor ini​ti​at​ing stem cells has
been dis​cov​ered in bor​der​line ovar​ian car​ci​noma that formed tu​mor
like spher​oids in vitro with spe​ci"c CSC like prop​er​ties [205]. In
ovar​ian can​cer, an in​creased methy​la​tion of tu​mor sup​pres​sor genes
is ob​served, among which BR​CA1 is a ma​jor mu​tated gene​
netic dis​rup​tor of BRCA-1 gene which has a ma​jor role in tu​mor ini​!
ti​a​tion and pro​gres​sion in ovar​ian can​cer. For ex​am​ple, AhR ac​ti​va​!
tion and CYP1 in​duc​tion by TCDD causes epi​ge​netic mod​i​"​ca​tions in
the BR​CA1 gene through CpG hy​per​me​thy​la​tion and hence si​lenc​ing
of BR​CA1 ex​pres​sion [187]. This ef​fect is at​trib​uted to the pres​ence
of sev​eral XREs at the prox​i​mal pro​moter re​gion of BRCA-1 that are
re​spon​si​ble for en​doge​nous AhR func​tion​ing [187]. In ad​di​tion, it
was re​ported that TCDD en​riched the crosstalk be​tween AhR and
DNA methyl trans​ferases-1, -3a, 3b; MBD-2, trimethy​lated H3K9
(H3K9me3), and the BR​CA1 pro​moter. The ob​ser​va​tions from this
study pro​vides ev​i​dence on the role of AhR ag​o​nists in BR​CA1 pro​!
moter hy​per​me​thy​la​tion. A tran​sient re​la​tion​ship be​tween AhR ex​!
pres​sion and DNA methy​la​tion sta​tus dur​ing em​bry​onic de​vel​op​ment
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re​pres​sive chro​matin struc​ture reg​u​lat​ing the stem cell dif​fer​en​ti​a​!
tion [210].
AhR is known to be ex​pressed in dif​fer​ent ovar​ian cells, in​clud​ing
fol​li​cles and oocytes in al​most all species. Al​though, PAHs, which are
po​tent AhR ac​ti​va​tors, are also known po​tent ovo​tox​i​cants, the role
of the AhR/​CYP1 path​way has not been ex​ten​sively in​ves​ti​gated in
en​dome​trial and ovar​ian can​cer. Ex​po​sure to TCDD, a well-known
AhR ag​o​nist, was found to stim​u​late pu​ber​tal mal​for​ma​tions and
ovar​ian dis​ease in 4 months old F3 gen​er​a​tion rats [211]. TCDD ex​!
po​sure of the fe​tus dur​ing go​nadal sex de​ter​mi​na​tion was also found
to al​ter the epi​ge​netic pro​gram​ming thereby trans​fer​ring the al​tered
epigenome to the next gen​er​a​tions pro​mot​ing dis​ease oc​cur​rence
[212]. In vivo an​i​mal study in​volv​ing the in​ves​ti​ga​tion of epi​ge​netic
trans​gen​er​a​tional ac​tiv​ity of TCDD has shown a higher in​ci​dence of
poly cys​tic ovar​ian dis​ease (PCOD) in the F1 and F3 gen​er​a​tions
[213]. Hav​ing known that PCOD is a pre​dis​pos​ing fac​tor for ovar​ian
can​cer, this "nd​ing can be clearly cor​re​lated with the in​volve​ment of
AhR in epi​ge​netic mod​i​"​ca​tion of the ovaries thereby act​ing as a
pre​dis​pos​ing fac​tor for the ovar​ian can​cer. A study mon​i​tor​ing the
DNA methy​la​tion analy​sis of rats ex​posed to TCDD iden​ti​"ed an in​!
creased hy​per​me​thy​la​tion in high dose TCDD in​duced rats. This
study also spec​u​lates that TCDD ex​po​sure to mother might lead to
pre​ma​ture ovar​ian fail​ure of the o&​spring rats [214]. In ad​di​tion, it
has been shown that daily ex​po​sure of im​ma​ture rats to 3MC, a po​!
tent AhR ac​ti​va​tor, in​creases ovar​ian can​cer stem​ness through AhR
bind​ing to pro​moter re​gions of CYP1A1 and genes in​volved in can​cer
stem​ness and pro​lif​er​a​tion such as Notch2, Hes1, Cy​clin D, and Akt,
an ef​fect which was blocked by $-NF, an AhR an​tag​o​nist, in​di​cat​ing
an AhR-de​pen​dent mech​a​nism [215]. In​duc​tion of these stem​ness
genes was shown to be at​trib​uted to 3MC-in​duced hi​s​tone mod​i​"​ca​!
tion, par​tic​u​larly trimethy​la​tion of H3 lysine4 (H3K4me3) and acety​!
la​tion of hi​s​tones H3 (H3K9Ac), lead​ing to ovar​ian dis​eases [215].
Fur​ther​more, ac​ti​va​tion of AhR/​CYP1A1 path​way us​ing 5F203 in
hu​man ovar​ian can​cer IGROV-1 cells in​duced DNA dou​ble strand
break which me​di​ated phos​pho​ry​la​tion of hi​s​tone H2AX, a marker
for can​cer pro​gres​sion [216], pro​duc​ing ,H2AX at the dou​ble strand
break site, which was blocked by the AhR an​tag​o​nist, $-NF [217],
con​"rm​ing that AhR ac​ti​va​tion is needed to in​duce hi​s​tone mod​i​"​ca​!
tion in ovar​ian can​cer. An​other pos​si​ble role of epi​ge​n​e​sis on the ef​!
fect of AhR in ovar​ian can​cer, is the mod​u​la​tion of AhR re​pres​sor,
AhRR. The in​volve​ment of AhRR, as a po​ten​tial tu​mor sup​pres​sor,
has been re​ported in dif​fer​ent can​cer types. It has been re​ported that
AhRR is down​reg​u​lated in can​cer through hy​per​me​thy​la​tion of its
pro​moter re​gion. Specif​i​cally, al​most 100% of ovar​ian can​cer tis​sues
ex​hib​ited AhRR hy​per​me​thy​la​tion, whereas no methy​la​tion was
found in nor​mal tis​sues [218]. There​fore, the ab​sence of AhRR ex​!
pres​sion in can​cer cells de​creases its com​pe​ti​tion with ARNT for
bind​ing to AhR and XRE, re​sult​ing in ac​ti​va​tion and in​duc​tion of its
tu​mor ac​ti​vat​ing genes, CYP1A1 and CYP1B1.
quences are also il​lus​trated in HCC [220]. Dif​fer​en​tial ex​pres​sion of
HDAC lev​els in CYP1A1 gene is also found in hu​man and mice he​!
patoma cells ac​count​ing for the dif​fer​en​tial ex​pres​sion of these genes
in both cells [221]. In ad​di​tion to HDAC-6, the in​duc​tion of AhR in
liver can​cer cells also in​creases the ex​pres​sion of HDAC-8 which re​!
presses tu​mor sup​pres​sor gene RB1, and thus pro​motes cell pro​lif​er​a​!
tion [219]. In an in vivo study on C3H mice with spon​ta​neous liver
tu​mor, it was re​ported that the dif​fer​en​tially methy​lated re​gions of
se​cre​tory leuko​cyte pep​ti​dase in​hibitor gene (SLPI), a ser​ine pro​tease
in​hibitor that is over​ex​pressed in var​i​ous types of can​cer, in​clud​ing
the core se​quence of XRE, and that hy​per​me​thy​la​tion of CpG in the
XRE core se​quence in SLPI may be in​volved in SLPI ex​pres​sion
through AhR ac​ti​va​tion [222].
The dif​fer​en​tial ex​pres​sion of miR-25 has been ob​served in a
num​ber of solid tu​mors [223]. In liver CSCs, miR-25 is over​ex​!
pressed com​pared to non-CSCs through mod​u​la​tion of PTEN ex​pres​!
sion in HepG2 cells. In that, knock​down of miR-25 in​creases ex​pres​!
sion of PTEN and the sen​si​tiv​ity of liver CSCs to TRAIL-in​duced
apop​to​sis [224]. There​fore, miR-25 is con​sid​ered as a po​ten​tial
onco​genic miRNA which is ac​ti​vated through AhR and that over​ex​!
pres​sion of this miRNA in liver CSCs re​duces their sen​si​tiv​ity to
TRAIL-in​duced apop​to​sis and its ex​pres​sion in these cells is also in​!
versely re​lated to PTEN ex​pres​sion. In ad​di​tion to the cor​re​la​tion of
miR-25 and AhR, a crosstalk be​tween NR2E3 and AhR has also been
re​ported, in that AhR and CYP1A1 ex​pres​sions in hu​man liver can​cer
HepG2 cell line has been found to be pos​i​tively reg​u​lated by NR2E3,
an or​phan nu​clear re​cep​tor and ox​ida​tive stress-re​spon​sive epi​ge​!
netic reg​u​la​tor that is over​ex​pressed in HCC. Loss of NR2E3 ex​pres​!
sion in in vivo mice (Rd7) and in in vitro HepG2 cells en​hanced hi​s​!
tone demethy​la​tion of hi​s​tone 3 ly​sine 4 di-methy​la​tion (H3K4me2),
to the AhR gene pro​moter re​gion, re​sult​ing in re​pres​sion of AhR
func​tion and CYP1A ex​pres​sion and en​zy​matic ac​tiv​i​ties [225].
These re​sults in​di​cate that AhR-me​di​ated liver can​cer oc​curs through
epi​ge​netic hi​s​tone mod​i​"​ca​tion by NR2E3.
5.4. Lung Cancer
Lung can​cer is the lead​ing cause of death glob​ally in both sexes
[226]. Ex​po​sure to en​vi​ron​men​tal pol​lu​tants such as PAHs has been
well linked to in​crease the risk of lung can​cer [56]. High in​ducibil​ity
of AhR/​CYP1A1 in smok​ers of to​bacco, which con​tains nu​mer​ous
PAHs, is known as a risk fac​tor for lung can​cer. Hy​pomethy​la​tion of
AhR reg​u​lated gene, AhRR, has been re​ported in smok​ers [227]. A
de​tailed study on the smok​ing as​so​ci​ated methy​la​tion of AhRR was
done ear​lier which found a pos​i​tive cor​re​la​tion with the time since
quit​ting of smok​ing, whereas showed a neg​a​tive cor​re​la​tion with the
num​ber of cig​a​rettes smoked per day and the uri​nary con​cen​tra​tion
of co​ti​nine [228]. An​other re​cent study con​ducted on non-smok​ers
aimed at as​sess​ing the as​so​ci​a​tion be​tween ex​po​sure to high con​cen​!
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In he​pa​to​cel​lu​lar car​ci​noma (HCC), AhR pro​motes tu​mori​ge​n​e​sis
in as​so​ci​a​tion with a proto-onco​gene, in​tes​tine-spe​ci"c home​obox
(ISX) [57]. In HCC, AhR is found to reg​u​late the epi​ge​netic hi​s​tone
acety​la​tion as well as deacety​la​tion by HAT and HDAC, re​spec​tively,
where im​bal​ance of these two en​zymes is as​so​ci​ated with can​cer.
AhR ac​ti​va​tion and HDAC over​ex​pres​sion is highly cor​re​lated in
HCC de​vel​op​ment, in that a con​comi​tant ex​pres​sion of HDAC en​!
zymes HDAC-1, -2, -3, -4, -7, -8, -9, and -10 was ob​served with
higher ex​pres​sion of AhR [219]. Fur​ther​more, ac​ti​va​tion of AhR
with TCDD in he​patoma cells leads to the ac​ti​va​tion of HDAC ex​!
pres​sion, which in turn binds to and then sup​presses the tu​mor sup​!
pres​sor gene, RB1. DNA methy​la​tion at the cy​tosines of CpG se
tra​tions of en​vi​ron​men​tal par​tic​u​late mat​ter PM , which is also
pos​i​tively re​lated to lung can​cer, and blood AhRR methy​la​tion at
cg05575921 showed in​verse re​la​tion​ship [229]. In​deed, sub​jects
who lived in ar​eas with higher PM  con​cen​tra​tions ex​hib​ited low
blood AhRR methy​la​tion lev​els. This is ex​plained by the fact that ar​!
eas with higher PM  are as​so​ci​ated with higher PAHs lev​els which
are po​ten​tial ac​ti​va​tors of AhR [230]. This is in agree​ment with
other stud​ies which showed that hy​pomethy​la​tion of AhRR us​ing
demethy​lat​ing agent, 5-aza-CdR or TSA in​creases its ex​pres​sion and
the risk and de​vel​op​ment of lung can​cer [46,218]. In con​trast to the
above men​tioned in​for​ma​tion, Chen et al., il​lus​trated that in​ac​ti​va​!
tion of the AhR path​way rather than hy​pomethy​la​tion of the re​pres​!
sor AHRR, is more im​por​tant and pos​si​bly leads to smok​ing-me​di​!
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DNA methy​la​tion of CYP1A1-me​di​ated PAH me​tab​o​lism was
found to be af​fected by smok​ing. Higher lev​els of hy​dropho​bic DNA
adduct due to methy​la​tion of CYP1A1 were ob​served in lung tu​mor
sam​ples when com​pared with cor​re​spond​ing his​to​log​i​cally nor​mal
lung from lung can​cer pa​tients [232]. In that, quan​ti​ta​tive analy​sis
of the DNA methy​la​tion lev​els at mul​ti​ple CpG sites of CYP1A1,
which car​ries three func​tional XREs, showed hy​per​me​thy​la​tion at
the en​hancer re​gion of CYP1A1 in lung can​cer [232]. On the other
hand, it has been re​ported that AhRR causes hi​s​tone deacety​la​tion of
XRE-con​tain​ing gene pro​mo​tor and hence ab​ro​ga​tion of the tran​!
scrip​tional ac​ti​va​tion of AhR lead​ing to re​duced risk of lung car​cino​!
gen​e​sis [46]. Co-ex​po​sure to AhR/​CYP1 in​ducer, BaP, and heavy
metal, Ar​senic (As), has been shown to syn​er​gis​ti​cally in​duce lung
can​cer CSCs, sphere for​ma​tion abil​ity, ALDH ex​pres​sion in in vitro
hu​man bronchial ep​ithe​lial BEAS-2B cells and in​crease lung tu​mori​!
genic​ity in in vivo mice model [233]. This syn​er​gis​tic ef​fect is at​trib​!
uted to the in​duc​tion of AhR and CYP1A1 ex​pres​sion caus​ing epi​ge​!
netic up​reg​u​la​tion of hi​s​tone H3 ly​sine 9 methyl​trans​ferase SU​!
V39H1 and H3 ly​sine 9 di​methy​la​tion (H3K9me2), which fur​ther de​!
creases the ex​pres​sion of tu​mor sup​pres​sive SOCS3 lead​ing to ac​ti​va​!
tion of Akt/​ERK, CSCs prop​er​ties, and tu​mori​genic​ity [233]. Fur​!
ther​more, ex​po​sure of AhR  mice to cig​a​rette smoke, which is
known to con​tain many PAHs such as BaP, sig​nif​i​cantly in​creases the
ex​pres​sion of miR-96, which pro​motes can​cer in​va​sions and metas​ta​!
sis [149].
5.5. Prostate Cancer
In​ci​dence of prostate can​cer is known to be pos​i​tively cor​re​lated
to ex​po​sure to en​vi​ron​men​tal pol​lu​tants, such as PAHs, that me​di​ate
AhR ac​ti​va​tion [234]. AhR is es​tab​lished to mod​u​late sev​eral sig​nal​!
ing path​ways in prostate can​cer, in that AhR and its reg​u​lated genes,
CYP1A1 and CYP1B1, were found to be over​ex​pressed in prostate
can​cer tis​sues and cell lines, whereas they were en​tirely ab​sent in be​!
nign prostate tis​sues and non-can​cer​ous cell lines [58,235,236]. The
ef​fect of can​cer re​lated epi​ge​netic mech​a​nisms on sup​press​ing PAH-
in​duced ac​ti​va​tion of CYP1A1 in prostate can​cer was an​a​lyzed by
Okino and co-work​ers who re​ported that DNA methy​la​tion in​hibitor,
5-aza-CdR, in​creases TCDD-in​duced CYP1A1 mRNA ex​pres​sion in
can​cer​ous LNCaP, but not in non-can​cer​ous PWR1E and RWPE-1
prostate cells [153]. An in​creased en​hancer methy​la​tion was also
ob​served in LNCaP can​cer cells that di​rectly in​hibit XRE func​tion,
but this was not ob​served in non-can​cer​ous prostate cells RWPE-1
cells, sug​gest​ing the role of AhR hy​per​me​thy​la​tion in prostate can​cer
pro​gres​sion. A lack of hi​s​tone mod​i​"​ca​tion es​pe​cially hi​s​tone acety​!
la​tion of H3 and H4, which are im​por​tant mark​ers of ac​tive genes,
was also ob​served in nor​mal prostate cells than can​cer cells upon
TCDD treat​ment [153]. This could be at​trib​uted to the re​cruit​ment
the ex​pres​sion of miR-150-5p via mi​to​gen-ac​ti​vated pro​tein 3 ki​nase
12 (MAP3K12)-me​di​ated mech​a​nism [69]. This an​tipro​lif​er​a​tive ef​!
fect of TCDD is re​versed by us​ing ei​ther miR-150-5p in​hibitor or
AhR knock​down [69].
5.6. Colorectal Cancer
Epi​ge​n​e​sis of the col​orec​tal can​cer has been re​cently re​viewed by
Goel and Roland [238]. AhR and its lig​ands; both en​doge​nous and
ex​oge​nous, are found to have a ma​jor role in the colon car​cino​gen​e​!
sis. A study car​ried out in seven col​orec​tal can​cer cell lines as well as
40 pri​mary col​orec​tal can​cer tis​sues, to in​ves​ti​gate the epi​ge​netic
mech​a​nisms for the ex​pres​sion of both CYP1A1 and CYP1B1 genes,
showed a hy​per​me​thy​la​tion in the pro​moter re​gion of CYP1B1, but
not in CYP1A1. In​ter​est​ingly, the CpG is​lands within the 5’ re​gion of
both genes were methy​lated in can​cer cells but not in pri​mary can​cer
tis​sue [165], sug​gest​ing a tis​sue-spe​ci"c epi​ge​netic reg​u​la​tion in col​!
orec​tal can​cer. In colon can​cer, en​hanced pro​moter methy​la​tion
thereby ac​ti​va​tion of Wnt/"-catenin path​way as well as si​lenc​ing of
Wnt in​hibitors genes such as WIF-1, AX​IN2, SFRP1, and Dick​kopf-re​!
lated pro​tein-1 (DKK1) were ob​served [239]. For in​stance, AhR lig​!
ands were re​ported to sig​nif​i​cantly in​#u​ence colonic stem cell home​!
osta​sis, gene ex​pres​sion, and reg​u​late their re​ac​tion to Wnt/"-catenin
path​way ini​ti​at​ing stem cell dif​fer​en​ti​a​tion as well as re​newal in col​!
orec​tal can​cer [240]. This "nd​ing sug​gests that AhR through its E3
ubiq​ui​tin lig​ase ac​tiv​ity, fa​cil​i​tates "-catenin ac​cu​mu​la​tion via tran​!
scrip​tional reg​u​la​tion of the Wnt/"-catenin path​way in​hibitors [240].
5.7. Leukemia, Multiple myeloma, and Neuroblastoma
Al​though the epi​ge​netic con​trol of AhR path​way has not been
thor​oughly stud​ied in leukemia, Rager and his col​leagues have
demon​strated that AhR ex​pres​sion and ac​tiv​ity are con​trolled by
mul​ti​ple miR​NAs, such as miR-125b, miR-126, miR-142-3p, miR-
155, miR-223, miR-29a, and miR-29b, which are known to play role
in leuke​mo​ge​n​e​sis [241]. In ad​di​tion, Scov​ille et al., have re​ported
that tran​scrip​tional ac​ti​va​tion of the AhR/​CYP1 path​way reg​u​lates
miR-129 ex​pres​sion in nat​ural killer (NK) cells lead​ing to im​pair​!
ment of NK func​tion and hence tu​mori​ge​n​e​sis, which is re​versed by
AhR an​tag​o​nist, CH223191 [54]. Ac​ti​va​tion of AhR with BaP and
TCDD in hu​man mul​ti​ple myeloma cells (MM1.s) ac​ti​vate the ex​pres​!
sion of sev​eral p53-tar​get​ing miR​NAs, such as miR-25, miR-15a,
miR-16, miR-92, miR-125b, miR-141, and miR-200a that in​ter​act
with the 3’-UTR of p53 gene lead​ing to re​pres​sion of p53 tu​mor sup​!
pres​sion ef​fect [55]. Huang and col​leagues have shown that AhR ac​!
ti​va​tion pro​motes neu​rob​las​toma cell growth. Fur​ther​more, in​!
creased AhR ex​pres​sion and ac​tiv​ity was re​ported to be neg​a​tively
con​trolled by miR-124 in 13 pa​tients with neu​rob​las​toma and also in
-/-
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of pro​teins with hi​s​tone acetyl trans​ferase ac​tiv​ity by AhR [237]. In
ad​di​tion, it has been re​ported that in​duc​tion of CYP1B1, but not
AhR, by TCDD in hu​man prostate ade​no​car​ci​noma PC-3 cells and
prostate can​cer tis​sues was po​ten​ti​ated by aber​rant CpG pro​moter/​
en​hancer hy​pomethy​la​tion as ev​i​denced by treat​ment with a DNA
methyl​trans​ferase in​hibitor, 5-aza-CdR [58]. These "nd​ings could be
ex​plained by the ob​ser​va​tions that AhR/​ARNT com​plex could not
bind to methy​lated XRE [151] as in the case of be​nign prostate sam​!
ples, in​di​cat​ing that epi​ge​netic hy​pomethy​la​tion of CYP1B1 and XRE
have a cru​cial role in prostate can​cer ini​ti​a​tion rather than pro​gres​!
sion [58].
The miR-150-5p and 3p are known tu​mor sup​pressers in prostate
can​cer and their down​reg​u​la​tion is linked to poor prog​no​sis. On con​!
trary to the car​cino​genic role of AhR, Yu and col​leagues have shown
that ac​ti​va​tion of AhR by TCDD sup​presses the pro​lif​er​a​tion and in​!
va​sion of prostate can​cer (PC-3 and DU145) cells through en​hanc​ing​
neu​rob​las​toma (SK-N-SH) cell lines, in which si​lenc​ing of miR-124
en​hanced AhR-in​duced neu​rob​las​toma cell pro​lif​er​a​tion [242].
6. Summary, Remarks, and Future directions
The emer​gence of CSCs in solid as well as hema​to​log​i​cal ma​lig​!
nan​cies have been a threat to treat​ment strate​gies. Sev​eral sig​nal​ing
cas​cades have been found rel​e​vant in im​part​ing chemore​sis​tance in
CSCs in sev​eral ma​lig​nan​cies thereby con​tribut​ing to poor prog​no​sis
and higher re​cur​rence and re​lapse. Since CSCs are known to be tu​!
mor-ini​ti​at​ing cells and are ma​jor tar​gets for chem​i​cal car​cino​gens, it
is highly pos​si​ble that these cells are reg​u​lated by the AhR. The role
of AhR/​CYP1 path​way in car​cino​gen​e​sis and can​cer ini​ti​a​tion as
well as its po​ten​tial use as a ther​a​peu​tic tar​get has been stud​ied in
all can​cer types. The func​tion of AhR in CSCs has re​cently gained at​!
ten​tion due to the se​vere im​pact of CSCs on chemore​sis​tance, dis​ease
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role of AhR in CSC reg​u​la​tion and pro​gres​sion in dif​fer​ent tu​mor
types is still very con​tro​ver​sial and re​quires reg​u​lar eval​u​a​tion and
sum​ma​riza​tion of re​cent in​sights in the "eld. The AhR/​CYP1 path​!
way is known to have tu​mor ac​ti​va​tor or sup​pres​sor ac​tiv​i​ties de​!
pend​ing on the phe​no​type of the tar​get can​cer cells. The hy​poth​e​sis
that AhR ac​ti​va​tion en​hances CSCs self-re​newal and pro​gres​sion, is
sup​ported by sev​eral re​ports which showed that CSCs of dif​fer​ent
can​cer types ex​hibit a higher ex​pres​sion and func​tional lev​els of AhR
than cor​re​spond​ing dif​fer​en​ti​ated non-CSCs. The ac​ti​va​tion of AhR
in​duces chemore​sis​tance through the ex​pres​sion of the CSC mark​ers
such as ALDH and SP. More​over, it fa​cil​i​tates the growth, main​te​!
nance, and pro​duc​tion of long-lived sec​ondary mam​mos​pheres, from
pri​mary prog​en​i​tor cells, through the ac​ti​va​tion of AKT/​Wnt/"-
catenin sig​nal​ing path​ways. In ad​di​tion, AhR sup​ports the pro​lif​er​a​!
tion, in​va​sion, metas​ta​sis, and sur​vival of the CSCs in chori​o​car​ci​!
noma, he​pa​to​cel​lu​lar car​ci​noma, oral squa​mous car​ci​noma, and
breast can​cers lead​ing to ther​apy fail​ure and tu​mor re​cur​rence. On
the other hand, the anti-tu​mor ef​fect of AhR is also sup​ported by
sev​eral stud​ies which showed that ac​ti​va​tion of AhR/​CYP1A in sev​!
eral can​cers re​presses spheres for​ma​tion and ex​pres​sion of Notch, "-
catenin, Nanog, and ALDH  cells [66]. The pres​ence of AhR lig​ands
such as TCDD, DMBA, and BaP ubiq​ui​tously in en​vi​ron​ment pro​!
motes can​cer in​va​sion and per​mits can​cer pro​gres​sion through epi​!
ge​netic mod​i​"​ca​tions. Ac​ti​va​tion of the AhR/​CYP1A1 path​way is
known to in​duce epi​ge​netic re​pres​sion of many tu​mor sup​pres​sor
genes such as BR​CA1, p53, AhRR and/​or ac​ti​va​tion of many tu​mor
ac​ti​vat​ing genes, such as WIF-1, "-catenin, and NOTCH, though mod​!
u​la​tion of their DNA methy​la​tion, hi​s​tone acety​la​tion/​deacety​la​tion,
and the ex​pres​sion of sev​eral miR​NAs. This makes AhR an im​por​tant
tar​get for de​vel​op​ment of anti-can​cer ther​a​pies. In can​cers, where
the treat​ment op​tions are lim​ited, the po​ten​tial of AhR can be ex​!
ploited for the de​vel​op​ment of new class of anti-can​cer drugs. Over​!
all, there is an es​sen​tial need to fur​ther un​der​stand the mol​e​c​u​lar
mech​a​nisms of epi​ge​netic reg​u​la​tion of CSCs by AhR for op​ti​mum
can​cer treat​ment, pa​tient sur​vival, and pre​ven​tion of chemore​sis​!
tance.
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